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Abstract
We currently understand the mental effects of psychedelics to be caused by agonism or partial agonism of 5-HT2A (and
possibly 5-HT2C) receptors, and we understand that psychedelic drugs, especially phenylalkylamines, are fairly selective for
these two receptors. This manuscript is a reference work on the receptor affinity pharmacology of psychedelic drugs. New
data is presented on the affinity of twenty-five psychedelic drugs at fifty-one receptors, transporters, and ion channels,
assayed by the National Institute of Mental Health – Psychoactive Drug Screening Program (NIMH-PDSP). In addition,
comparable data gathered from the literature on ten additional drugs is also presented (mostly assayed by the NIMH-PDSP).
A new method is introduced for normalizing affinity (Ki) data that factors out potency so that the multi-receptor affinity
profiles of different drugs can be directly compared and contrasted. The method is then used to compare the thirty-five
drugs in graphical and tabular form. It is shown that psychedelic drugs, especially phenylalkylamines, are not as selective as
generally believed, interacting with forty-two of forty-nine broadly assayed sites. The thirty-five drugs of the study have very
diverse patterns of interaction with different classes of receptors, emphasizing eighteen different receptors. This diversity of
receptor interaction may underlie the qualitative diversity of these drugs. It should be possible to use this diverse set of
drugs as probes into the roles played by the various receptor systems in the human mind.
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Introduction
We currently understand the mental effects of psychedelics
to be caused by agonism or partial agonism of 5-HT2A (and
possibly 5-HT2C) receptors (serotonin-2A and serotonin-2C
receptors) [1]. This understanding was first developed in the
1980s [2–4] and has since been confirmed by a large body of
evidence, as reviewed recently by Nichols [1]. However, many
authors have commented that other receptors may also play a
role [1,3,5–9]. In this post-genome era of high-throughput
assays, it is time to take a broader view, move beyond the
common-denominator approach [6], and begin to explore the
role of other receptors in shaping the mental effects of
psychedelics, especially the qualitative differences among
them.
The objective of this paper is to present the receptor binding
profiles of the thirty-five drugs (Fig. 1, Fig. 2) of this study in
such a way that they can be easily compared in both their
similarities and their differences. This is intended to serve as a
reference work on the multi-receptor affinity pharmacology of
psychedelic drugs. The tables and figures are the heart of this
manuscript. Some of them have been included as ‘‘supporting
information,’’ because they exceed the size limits of standard
tables and figures. However, this supporting information is no
less central to the manuscript than the standard tables and
figures.
Methods
Data from Literature
Data on receptor interactions of ten compounds (Fig. 2) has been
collected from the literature. The four ergolines (LSD, cis-2a, RR-
2b, and SS-2c) were assayed by NIMH-PDSP against forty-three
receptors, transporters and ion channels [10]. Salvinorin A was
assayed by NIMH-PDSP against thirty receptors and transporters
[11]. EMDT and 5-MeO-TMT were assayed by NIMH-PDSP
against forty receptors, transporters and ion channels [12].
Receptor data for ibogaine (Table S1), morphine (Table 1) and
THC (Table 2) was collected from a variety of sources. While ibogaine
has been assayed at a wide variety of receptors, morphine and THC
have not, so their data should be used with caution. Although
morphine is not considered to be a psychedelic, and ibogaine, THC,
and salvinorin A are not considered to be ‘‘classical hallucinogens,’’
these four compounds are included because they provide insights into
additional receptor systems (salvinorin A – k (kappa opioid receptor),
ibogaine – s (sigma receptor) and k, THC – CB (cannabinoid
receptor), morphine – m (mu opioid receptor)). These additional
compounds could also be thought of as active controls, as compared to
the three presumably inactive controls of Fig. 1.
New PDSP Binding Assays
For this study, the NIMH-PDSP (http://pdsp.med.unc.edu/)
has assayed sixteen phenylalkylamines, eight tryptamines and one
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ergoline (twenty-two psychedelics and three controls, Fig. 1)
against a panel of fifty-one receptors, transporters, and ion
channels. The methodology has been described previously by
Glennon et al. [12]. Each compound is initially assayed at 10 mM
against each receptor, transporter or ion channel (primary assay).
Those that induce .50% inhibition (‘‘hit’’) are then assayed at 1,
10, 100, 1,000, and 10,000 nM to determine Ki values (secondary
assay). Each Ki value (equilibrium dissociation constant, concen-
tration at which 50% of the hot ligand is displaced by the test
ligand) is calculated from at least three replicated assays. Details of
how individual assays were conducted can be found at the NIMH-
PDSP web site: http://pdsp.med.unc.edu/pdspw/binding.php.
Table S2 shows raw Ki data for the current study combined
with data collected from the literature for the ten additional
compounds; a total of thirty-five drugs and sixty-seven receptors,
transporters and ion channels which were assayed. The table has
been divided into three sections.
The first section displays forty-two sites at whichmost compounds
were assayed and at least one ‘‘hit’’ (Ki ,10,000 nm) was found:
5ht1a (5-HT1A, serotonin-1A receptor), 5ht1b (5-HT1B, serotonin-
1B receptor), 5ht1d (5-HT1D, serotonin-1D receptor), 5ht1e (5-
HT1E, serotonin-1E receptor), 5ht2a (5-HT2A, serotonin-2A
receptor), 5ht2b (5-HT2B, serotonin-2B receptor), 5ht2c (5-HT2C,
serotonin-2C receptor), 5ht5a (5-HT5A, serotonin-5A receptor),
5ht6 (5-HT6, serotonin-6 receptor), 5ht7 (5-HT7, serotonin-7
receptor), D1 (D1, dopamine-1 receptor), D2 (D2, dopamine-2
receptor), D3 (D3, dopamine-3 receptor), D4 (D4, dopamine-4
receptor), D5 (D5, dopamine-5 receptor), Alpha1A (a1A, alpha-1A
adrenergic receptor), Alpha1B (a1B, alpha-1B adrenergic receptor),
Alpha2A (a2A, alpha-2A adrenergic receptor), Alpha2B (a2B, alpha-
2B adrenergic receptor), Alpha2C (a2C, alpha-2C adrenergic
receptor), Beta1 (b1, beta-1 adrenergic receptor), Beta2 (b2, beta-2
adrenergic receptor), SERT (serotonin transporter), DAT (dopa-
mine transporter), NET (nor epinephrine transporter), Imidazoline1
(I1, imidazoline-1 receptor), Sigma1 (s1, sigma-1 receptor), Sigma2
(s2, sigma-2 receptor), DOR (delta opioid receptor), KOR (k,
kappa opioid receptor), MOR (m, mu opioid receptor), M1 (M1,
muscarinic-1 acetylcholine receptor), M2 (M2, muscarinic-2
acetylcholine receptor), M3 (M3, muscarinic-3 acetylcholine
receptor), M4 (M4, muscarinic-4 acetylcholine receptor), M5 (M5,
muscarinic-5 acetylcholine receptor), H1 (H1, histamine-1 receptor),
H2 (H2, histamine-2 receptor), CB1 (CB1, cannabinoid-1 receptor),
CB2 (CB2, cannabinoid-2 receptor), Ca+Channel (calcium+ ion
channel), NMDA/MK801 (N-methyl D-aspartate glutamate
receptor).
The second section displays seven sites at which most
compounds were assayed, but at which there were no hits: 5ht3
(serotonin-3 receptor), H3 (histamine-3 receptor), H4 (histamine-4
Figure 1. Twenty-five drugs assayed for this study by the NIMH-PDPS. Twenty-five drugs assayed for this study by the NIMH-PDPS against
fifty-one receptors, transporters and ion-channels. The twenty-five drugs include sixteen phenylalkylamines, eight tryptamines, and one ergoline. The
three control drugs on the right include one representative from each structural class, and are believed to be non-psychedelic.
doi:10.1371/journal.pone.0009019.g001
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receptor), V1 (vasopressin-1 receptor), V2 (vasopressin-2 receptor),
V3 (vasopressin-3 receptor), GabaA (GABA-A receptor).
The third section displays the remaining eighteen sites, at which
only a few compounds were assayed, and no hits were found:
GabaB (GABA-B receptor), mGluR1a (mGluR1a metabotropic
glutamate receptor), mGluR2 (mGluR2 metabotropic glutamate
receptor), mGluR4 (mGluR4 metabotropic glutamate receptor),
mGluR5 (mGluR5 metabotropic glutamate receptor), mGluR6
(mGluR6 metabotropic glutamate receptor), mGluR8 (mGluR8
metabotropic glutamate receptor), A2B2 (nicotinic a2/b2 acetyl-
choline receptor), A2B4 (nicotinic a2/b4 acetylcholine receptor),
A3B2 (nicotinic a3/b2 acetylcholine receptor), A3B4 (nicotinic
a3/b4 acetylcholine receptor), A4B2 (nicotinic a4/b2 acetylcho-
line receptor), A4B2** (nicotinic a4/b2** acetylcholine receptor),
A4B4 (nicotinic a4/b4 acetylcholine receptor), BZP (a1) (GABA-
BZP a1 receptor), EP3 (prostaglandin-3 receptor), MDR 1
(multidrug resistant p-Glycoprotein), PCP (PCP glutamate
receptor).
Activity Assays
For the twenty-five compounds of Fig. 1, the NIMH-PDSP also
performed activity assays at 5-HT2A and 5-HT2C. The Emax values
(maximal activity) are relative to 5-HT (serotonin), measuring
Ca++ mobilization. Ca++ flux assays were performed using a
FLIPRTETRA. The activity assays were conducted with cell lines
which have very high receptor expression levels (e.g. plenty of
‘spare receptors’). Under such conditions partial agonists will have
considerable agonist activity. The data represent the mean 6
variance of computer-derived estimates from single experiments
done in quadruplicate. Thus, the four observations are averaged
and a single estimate with error is provided (Table S3).
Sources
The following compounds (Fig. 1) were used in the study:
N 2C-B, 4-Bromo-2,5-dimethoxyphenethylamine
N 2C-B-fly, 1-(8-Bromo-2,3,6,7-tetrahydrobenzo[1,2-b;4,5-b9]di-
furan-4-yl)2-aminoethane
N 2C-E, 4-Ethyl-2,5-dimethoxyphenethylamine
N 2C-T-2, 4-Ethylthio-2,5-dimethoxyphenethylamine
N ALEPH-2, (6)-4-Ethylthio-2,5-dimethoxyamphetamine
N 4C-T-2, 4-Ethylthio-2,5-dimethoxyphenylbutylamine
N MEM, (6)-2,5-Dimethoxy-4-ethoxyamphetamine
N TMA-2: (6)-2,4,5-Trimethoxamphetamine
N TMA: (6)-3,4,5-Trimethoxamphetamine
N mescaline: 3,4,5-Trimethoxyphenethylamine
N DOB: (6)-2,5-Dimethoxy-4-bromoamphetamine
N DOI: (6)-2,5-Dimethoxy-4-iodoamphetamine
N DOM: (6)-2,5-Dimethoxy-4-methylamphetamine
N DOET: (6)-2,5-Dimethoxy-4-ethylamphetamine
N MDA: (6)-3,4-Methylenedioxyamphetamine
N MDMA: (6)-3,4-Methylenedioxymethamphetamine
N DMT: N,N-Dimethyltryptamine
Figure 2. Ten drugs whose receptor profiles were collected from the literature. Ten drugs whose receptor profiles were collected from the
literature. All but ibogaine, THC, and morphine were assayed by the NIMH-PDSP.
doi:10.1371/journal.pone.0009019.g002
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N 5-MeO-DMT: 5-Methoxy-N,N-dimethyltryptamine
N DPT: N,N-Dipropyltryptamine
N 5-MeO-MIPT: 5-Methoxy-N-methyl-N-isopropyltryptamine
N DIPT: N,N-Diisopropyltryptamine
N 5-MeO-DIPT: 5-Methoxy-N,N-diisopropyltryptamine
N 6-fluoro-DMT: 6-Fluoro-N,N-dimethyltryptamine
N psilocin: 4-Hydroxy-N,N-dimethyltryptamine
N lisuride
5-MeO-DMT, and DOI were purchased from Sigma. DOB,
DOET, mescaline, TMA, MDA, MDMA, and psilocin were
provided as gifts by the National Institute on Drug Abuse Drug
Supply Program. 2C-B, 2C-B-fly, MEM, 4C-T-2, 5-MeO-MIPT,
6-fluoro-DMT, TMA-2, and lisuride were provided as gifts by
Dave Nichols. DMT and DOM were provided as gifts by Richard
Glennon. 2C-E, 2C-T-2, Aleph-2, DIPT, 5-MeO-DIPT, and
DPT were provided as gifts by Alexander Shulgin.
Normalization
The raw Ki values are distributed over several orders of
magnitude, thus a log transformation is a good first step in the
analysis. In addition, higher affinities produce lower Ki values,
thus it is valuable to calculate: pKi =2log10(Ki). Higher affinities
have higher pKi values, and each unit of pKi value corresponds to
one order of magnitude of Ki value. Table S4 presents the raw
data transformed into pKi values. Generally, the highest Ki value
generated by NIMH-PDSP is 10,000, which produces a pKi value
of24 (although a value of 10,450 was reported for 5-MeO-TMT).
For non-PDSP data gathered from the literature, some Ki values
greater than 10,000 are reported (i.e. 12,500, 14,142, 22,486,
39,409 and 70,000 for ibogaine).
When the primary assay did not produce .50% inhibition, the
Ki value is treated as .10,000. When the primary assay hit, but
the secondary assay was not performed, the Ki value is also treated
as .10,000. If a secondary assay produced a Ki value significantly
greater than 10,000, it is usually also reported as .10,000. The
lowest Ki value in the data set of this study is 0.3 (lisuride at 5-
HT1A) and the highest value is 70,000 (ibogaine at D3), thus
collectively, the data in this study cover nearly six orders of
magnitude of Ki values. However, ignoring values reported as
.10,000, the Ki values for a single drug in this study never exceed
four orders of magnitude in range.
The goal of the normalization used in this study is to factor out
potency, in order to allow easy comparison of the multi-receptor
affinity profiles of different drugs. The normalization will adjust
Table 1. Receptor affinity data for morphine.
Receptors Hot Ligand Source Tissue Ki(nM) IC50(nM) Reference
KOR 3H-U69,593 GUINEA PIG ILEUM 217649 PDSP; [17]
3H-U69,593 Human cloned 134622 PDSP; [18]
[Dmt]DALDA Human cloned 4.461.7 [19]
DMAGO Human cloned 213628 [19]
[3H]U69593 rat Brain 11369 PDSP; [20]
50 average human
MOR 3H-DAMGO GUINEA PIG ILEUM 160.04 PDSP; [17]
3H-Diprenorphine Human cloned 2.0660.48 PDSP; [18]
3H-Dmt-DALDA mouse Brain 5.6460.24 PDSP; [19]
[Dmt]DALDA human cloned 0.17260.026 [19]
DMAGO human cloned 1.18060.120 [19]
[3H]DAMGO rat Brain 6.5560.74 PDSP; [20]
HEK-m cells 2.260.5 [21]
[3H]DAMGO human BE(2)-C memberanes 1.0260.15 PDSP; [22]
bovine adrenals 1.86 [23]
0.81 average human
DOR 3H-DSLET MOUSE vas deferens 32.663.7 PDSP; [17]
3H-Naltrindole Human cloned .10,000 PDSP; [18]
[Dmt]DALDA human cloned 1670640 [19]
DMAGO human cloned 1430620 [19]
[3H][Ile5,6]deltorphin II rat Brain 217619 PDSP; [20]
278649 [24]
[3H]DPDPE human BE(2)-C memberanes .100 PDSP; [22]
[3H]enkephalin rat memberane 69.163.2 [25]
bovine adrenals 147.32 [23]
1545 average human
Receptor affinity data for morphine collected from the literature. The columns identify the receptor, the radioligand used in determining affinity, the source species from
which the receptor was used, the tissue from which the receptor was used, the Ki value in nanomoles or the IC50 (the molar concentration of an unlabeled agonist or
antagonist that inhibits the binding of a radioligand by 50%, [26]) value in nanomoles, and the literature reference from which the data was obtained.
doi:10.1371/journal.pone.0009019.t001
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the highest pKi value for each drug to a value of 4, and set all Ki
values reported as .10,000 to a value of zero. Ki values actually
measured as greater than 10,000 are not set to zero (i.e. 5-MeO-
TMT and ibogaine). We will call this normalized value npKi. Let
the maximum pKi value for each drug be called pKiMax. For each
individual drug:
N If Ki treated as .10,000, then npKi = 0
N npKi = 4+pKi2pKiMax
With this normalization:
N higher affinities have higher values
N affinities too low to be measured will be reported as zero
N for each drug, the highest affinity will be set to a value of 4
N each unit of npKi value represents one order of magnitude of
Ki value
N potency is factored out so that drugs of different potencies can
be directly compared
This normalization effectively factors out the absolute potency
of each drug, and allows us to focus on the relative affinities of
each drug at each receptor.
Perceptibility
It will also be seen that many psychedelic drugs interact with a
large number of receptors. Fig. 3 shows the ranked distributions of
npKi values for DOB and DOI, and the same data is listed below
in numerical form (0.00 means Ki .10,000, ND means the data is
not available):
DOB: 4.00 5ht2b, 3.23 5ht2a, 2.97 5ht2c, 2.11 Beta2, 1.89
5ht7, 1.82 Alpha2C, 1.79 5ht1d, 1.68 D3, 1.62 5ht1b, 1.53 M3,
1.44 5ht1e, 1.41 Alpha2B, 1.39 Imidazoline1, 1.25 Sigma1, 1.21
Beta1, 1.18 5ht1a, 0.96 Alpha2A, 0.87 5ht5a, 0.85 5ht6, 0.66
SERT, 0.63 H1; 0.00: D5, D2, D4, NET, D1, Alpha1B, Sigma2,
DOR, KOR, MOR, M1, M2, DAT, M4, M5, Alpha1A, H2,
CB2, CB1, Ca+Channel, NMDA
DOI: 4.00 5ht2c, 3.79 Alpha2A, 3.52 Beta2, 3.44 5ht2a, 3.13
Alpha2B, 3.13 5ht2b, 3.00 5ht1d, 2.90 M4, 2.89 Beta1, 2.88
Alpha2C, 2.83 SERT, 2.66 5ht1e, 2.51 M3, 2.42 H1, 2.36 M2,
2.34 5ht6, 2.32 M5, 2.31 5ht1a, 2.23 M1, 1.90 5ht7, 1.73 Sigma1,
1.70 Sigma2, 1.67 D1; 0.00: 5ht1b, DAT, Imidazoline1, NET,
5ht5a, DOR, KOR, MOR, Alpha1B, D2, D3, D4, D5, Alpha1A,
H2, CB2, CB1, NMDA; ND: Ca+Channel
For potent compounds like DOB and DOI, it is possible to
measure Ki values over nearly a full four orders of magnitude
range of affinity. However, not all of these affinities are able to
produce perceptible mental effects. As a rule of thumb, 100-fold
affinity is considered truly selective. Thus, receptors with npKi
values below about 2.0 should not have perceptible mental effects.
In Fig. 3, a black vertical bar represent a 100-fold drop in affinity
relative to the receptor with the highest affinity, and divides those
npKi values greater than 2.0 (on the left) from those 2.0 or less (on
the right). This is presumed to be the limit of perceptible receptor
interaction. Receptors to the right of the black bar should be
imperceptible, while receptors to the left of the black bar should be
perceptible, increasingly so the further left they are. In spite of the
long tail of affinities, DOB is effectively selective for the three 5-
Table 2. Receptor affinity data for THC.
Receptors hot ligand source tissue Ki(nM) Ref
CB1 3H-BAY 38-7271 HUMAN CORTICAL
MEMBRANES
13.7 PDSP; [27]
3H-BAY 38-7271 HUMAN CLONED 15.3 PDSP; [28]
3H-CP-55940 HUMAN CLONED 5.05 PDSP; [29]
10.19 average
CB2 3H-BAY 38-7271 HUMAN CLONED 25.06 PDSP; [28]
3H-BAY 38-7271 HUMAN CLONED 22.9 PDSP; [27]
3H-CP-55940 HUMAN CLONED 44.9 [30]
3H-CP-55940 HUMAN CLONED 3.13 PDSP; [29]
16.85 average
sigma 3H-3-PPP,(+) RAT BRAIN .100,000 PDSP; [31]
Receptor affinity data for THC collected from the literature. The columns
identify the receptor, the radioligand used in determining affinity, the source
species from which the receptor was used, the tissue from which the receptor
was used, the Ki value in nanomoles, and the literature reference from which
the data was obtained.
doi:10.1371/journal.pone.0009019.t002
Figure 3. Receptor affinity profiles of DOB and DOI, ordered by decreasing affinity. The vertical axis is normalized pKi (npKi). Horizontal
axis is a list of forty-two receptors, arranged in order of decreasing affinity for each individual drug. Colors correspond to classes of receptors, and are
the same as used in Fig. S1. The black vertical bars represent a 100-fold drop in affinity relative to the receptor with the highest affinity. As a rule of
thumb, this is presumed to be the limit of perceptible receptor interaction. Receptors to the right of the black bar should be imperceptible, while
receptors to the left of the black bar should be perceptible, increasingly so the further left they are.
doi:10.1371/journal.pone.0009019.g003
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HT2 (serotonin-2) receptors (Beta2 falls at the approximate limit of
perceptibility), while DOI by contrast has nineteen receptors in the
presumed perceptible range, although they should not all be
equally perceptible.
Breadth
An index of the breadth (or inverse of selectivity), B, of the
binding profiles of the individual drugs or receptors can be
constructed by summing the forty-two npKi values for each drug,
or the thirty-five npKi values for each receptor. If a drug were
absolutely selective, binding at only one receptor (e.g. salvinorin
A), it would have the minimal B value of 4, regardless of the
absolute affinity of the drug for its one receptor. If a drug bound
with equal affinity to all forty-two receptors, it would have the
maximum B value of 4642= 168, regardless of its absolute
receptor affinities.
It is not clear that a simple sum of npKi values is the best index
of breadth. In this method, four receptors with Ki values of 1,000
collectively carry the same weight as one receptor with a Ki value
of 1. This may not be a realistic equivalence. Thus we will include
three measures of breadth:
B~
X
npKi
Bsq~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃX
(npKi)
2
q
Bexp~ ln (
X
enpKi )
Bsq and Bexp give greater weight to higher affinity (lower Ki)
values. Regression analysis of receptor affinity vs. potency in
humans suggests that Bsq is the most meaningful breadth statistic.
Table S5 and Table S6 present the raw Ki data converted into
npKi values, for both the individual receptors, and groups of
receptors summed using the Bsq statistic.
Proportional Breadth
In addition to looking at the breadth of interaction of individual
drugs with multiple receptors, it may be of value to look at an
individual drug’s interaction with one receptor or group of
receptors, as a proportion of the drug’s total interaction with all
receptors.
In order to compute the proportion for and individual receptor
or a group of receptors, we divide the sum of squares of npKi
values for the group of receptors, by the sum of squares of npKi
values for all receptors:
Bp~
P
Group
npKi
2
P
All
npKi
2
For example, to compute this proportion for ‘‘5-HT’’ receptors,
we divide the squares of the values in the ‘‘5-HT’’ column of
Table S5 (for LSD, 11.132= 123.9), by the squares of the values in
the center column (‘‘Bsq’’) of Table 3 (for LSD, 13.12
2 = 172.1);
123.9/172.1 = 0.719 for LSD. We will call this proportion Bp.
The proportional breadth data is displayed in Table S7 and
Table S8.
Truncated Receptor Profiles
The NIMH-PDSP generally does not measure Ki values greater
than 10,000 nm, because at those concentrations, there is a great
deal of non-specific binding which invalidates the measurement of
receptor affinity. This creates a problem for drugs whose best-hit
has a Ki value of greater that 100 nm (TMA, mescaline, TMA-2,
DIPT, MDMA, 5-MeO-DIPT, ibogaine). For these drugs, the
range of Ki values that can be measured by the NIMH-PDSP is
less than the 100-fold presumed perceptible range, and therefore,
the lowest measurable npKi value is greater than the presumed
limit of perceptibility at 2.00. Table 4 shows for each drug, the
Table 3. Thirty-five drugs arranged in order of decreasing
breadth, increasing selectivity.
B Drug Bsq Drug Bexp Drug
67.5 6-F-DMT 14.19 6-F-DMT 6.22 6-F-DMT
63.5 DPT 13.34 DMT 6.16 DMT
61.6 DOI 13.30 DPT 6.12 LSD
56.4 LSD 13.21 DOI 6.02 DPT
54.3 DMT 13.12 LSD 6.02 DOI
50.5 lisuride 11.88 lisuride 5.93 TMA
45.3 2C-E 11.61 2C-E 5.85 lisuride
45.2 cis-2a 11.55 TMA 5.81 2C-E
45.2 5-MeO-MIPT 11.37 2C-B 5.77 2C-B
43.9 2C-B 11.29 cis-2a 5.75 cis-2a
42.1 psilocin 11.00 5-MeO-MIPT 5.70 5-MeO-MIPT
40.5 2C-T-2 10.71 psilocin 5.60 psilocin
38.1 TMA 10.21 DIPT 5.52 DIPT
37.6 RR-2b 9.85 5-MeO-DIPT 5.49 5-MeO-DIPT
34.9 DIPT 9.80 RR-2b 5.44 4C-T-2
34.7 5-MeO-DMT 9.65 2C-T-2 5.44 RR-2b
34.5 DOB 9.64 4C-T-2 5.44 MDMA
33.4 SS-2c 9.50 MDMA 5.41 DOET
33.3 DOET 9.35 ibogaine 5.38 mescaline
32.5 2C-B-fly 9.32 DOET 5.36 2C-T-2
32.1 5-MeO-DIPT 9.00 5-MeO-DMT 5.36 5-MeO-DMT
31.2 ibogaine 8.85 SS-2c 5.35 ibogaine
31.1 4C-T-2 8.67 2C-B-fly 5.29 2C-B-fly
28.2 MDMA 8.67 mescaline 5.24 5-MeO-TMT
28.1 DOM 8.44 DOB 5.22 SS-2c
27.0 Aleph-2 8.41 5-MeO-TMT 5.16 DOB
22.9 5-MeO-TMT 8.29 DOM 5.10 DOM
21.1 mescaline 7.89 MDA 5.07 MDA
20.4 MDA 7.30 Aleph-2 4.94 Aleph-2
18.4 EMDT 7.22 EMDT 4.86 EMDT
13.0 TMA-2 6.60 TMA-2 4.78 TMA-2
10.3 MEM 5.50 THC 4.59 THC
7.8 THC 5.40 MEM 4.37 MEM
6.9 morphine 4.63 morphine 4.19 morphine
4.0 salvinorin A 4.00 salvinorin A 4.00 salvinorin A
The thirty-five drugs are arranged in order of decreasing breadth and increasing
selectivity, based on the breadth indices B, Bsq, and Bexp. Although the three
indices provide different orderings, the orderings are quite similar at the two
extremes of the table (greatest and least breadth) where most of the attention
is likely to be focused. The drugs with the broadest receptor interactions (least
selective) are found at the tops of the columns, and the drugs with the
narrowest receptor interactions (most selective) are found at the bottoms of the
columns.
doi:10.1371/journal.pone.0009019.t003
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lowest Ki value measured (KiMin) which is the best-hit, the best-hit
receptor (KiMinR), the theoretically lowest measurable npKi value
(npKiLim), the lowest actually measured npKi value (npKiMin),
and the receptor where the lowest npKi value was actually
measured (npKiMinR). Drugs that have both a KiMin value of
greater that 100 nm and an npKiMin value greater than 2.00 have
truncated receptor affinity profiles.
Seven drugs have best-hit Ki values of greater that 100 nm:
TMA, mescaline, TMA-2, DIPT, MDMA, 5-MeO-DIPT,
ibogaine. For these seven drugs, the perceptible receptor profile
is truncated due to the methodological limitations of the NIMH-
PDSP, to the extent to which the npKiMin value is greater than
2.00. Note that for ibogaine, whose best hit is 206 nm, the
npKiMin value is 1.47, indicating that the receptor profile is not
fully truncated, because several Ki values above 10,000 nm were
gathered from the literature (however, ibogaine has not received a
full receptorome screening, and thus its receptor profile must be
considered incomplete for other reasons).
Six drugs have both a KiMin value of greater that 100 nm and
an npKiMin value greater than 2.00. For 5-MeO-DIPT, the
npKiMin value (2.15) is close to the presumed perceptibility limit,
thus we can consider its receptor profile to be complete. For TMA-
2, DIPT, and MDMA, the npKiMin values (2.58, 2.51, 2.43
respectively) fall in the weak region of the presumed perceptibility
range. Although these three receptor profiles are truncated, the
missing data may be of little consequence. For TMA and
mescaline, the npKiMin values (2.98. 2.92 respectively) fall in
the moderate region of the presumed perceptibility range. We
must consider these two truncated receptor profiles to be truly
incomplete, with potential consequences for our interpretations of
the properties of these two drugs. The receptor profiles of some
other drugs are incomplete due to holes in the NIMH-PDPS data
set. Morphine and THC have not been broadly assayed, and must
also be considered to be incomplete.
Results
Normalized Affinity Data
Fig. S1 shows the simplest view of the normalized affinity data.
The drugs in Fig. S1 are ordered to correspond roughly to
similarity of structure and receptor affinity profiles. Colors
correspond to classes of receptors. It can be seen at a glance that
most, but not all of the drugs interact strongly with the serotonin
receptors (beige), certain drugs interact strongly with the dopamine
receptors (red), others with the adrenergic receptors (green), yet
others with the histamine receptors (yellow), etc.
Breadth
In Table 3, the thirty-five drugs are arranged in order of
decreasing breadth and increasing selectivity, based on the three
breadth indices B, Bsq, and Bexp. Although the three indices
provide different orderings, the orderings are quite similar at the
two extremes of the table (greatest and least breadth) where most
of the attention is likely to be focused. The drugs with the broadest
receptor interactions (least selective) are found at the tops of the
columns, and the drugs with the narrowest receptor interactions
(most selective) are found at the bottoms of the columns.
Regression analysis suggests that Bsq is the best statistic for
combining receptors, therefore the Bsq statistic will be used in most
of the breadth analyses to follow. The B, Bsq and Bexp data of
Table 3 is presented graphically in Fig. 4.
Profiles of Drugs
The relative breadth or selectivity of the thirty-five drugs is
nicely visualized in Fig. S2, in which for each drug, the bars
representing forty-two receptors are arranged in order of
decreasing size. The drugs are arranged in order of decreasing
breadth, based on the Bsq values of Table 3 and Fig. 4. Drugs at
the top of the figure have the broadest receptor interactions (least
selective), while drugs at the bottom of the figure have the
narrowest receptor interactions (most selective). Colors correspond
to classes of receptors, and are the same as used in Fig. S1.
Scanning Fig. S2 from top to bottom shows the variation in
breadth of receptor interactions between drugs. It can also be seen
Table 4. Truncated receptor profiles for thirty-five drugs.
Drug KiMin KiMinR npKiLim npKiMin npKiMinR
mescaline 745.3 Alpha2C 2.87 2.92 Alpha2A
TMA 476.6 5ht2b 2.68 2.98 Alpha2C
MDMA 219.7 Imidazoline1 2.34 2.43 M4
ibogaine 206 Sigma2 2.31 1.47 D3
TMA-2 154.4 5ht2b 2.19 2.58 5ht2c
5-MeO-DIPT 132.4 5ht1a 2.12 2.15 Sigma1
DIPT 120.5 5ht1a 2.08 2.51 5ht1d
MDA 91 5ht2b 1.96 2.15 5ht2c
DMT 87.5 5ht7 1.94 2.23 Sigma1
MEM 64.5 5ht2b 1.81 1.95 5ht7
5-MeO-TMT 60 5ht6 1.78 1.76 5ht5a
4C-T-2 58.1 5ht2b 1.76 1.77 5ht1e
DOI 45.8 5ht2c 1.66 1.67 D1
DPT 31.8 5ht1a 1.50 1.54 D2
6-F-DMT 25.6 5ht6 1.41 1.56 Sigma2
2C-E 25.1 5ht2b 1.40 1.88 D2
EMDT 16 5ht6 1.20 1.54 5ht5a
DOET 14.4 5ht1a 1.16 1.17 Sigma1
2C-B 13.5 5ht2b 1.13 1.28 D3
5-MeO-MIPT 12.3 5ht1a 1.09 1.28 SERT
DOM 11.7 5ht2b 1.07 1.16 5ht6
THC 10.19 CB1 1.01 3.78 CB2
2C-T-2 6 5ht2b 0.78 0.81 Beta1
psilocin 4.7 5ht2b 0.67 1.03 Alpha2C
salvinorin A 4.3 KOR 0.63 4 KOR
LSD 3.9 5ht1b 0.59 0.65 Alpha1B
DOB 3.9 5ht2b 0.59 0.63 H1
cis-2a 2.3 5ht1a 0.36 0.7 Beta2
RR-2b 2 5ht1b 0.30 0.59 Alpha1A
5-MeO-DMT 1.9 5ht1a 0.28 0.69 5ht2b
Aleph-2 1.6 5ht2b 0.20 0.3 M5
2C-B-fly 0.9 5ht2b 20.05 0.12 D2
morphine 0.81 MOR 20.09 0.72 DOR
SS-2c 0.4 5ht1a 20.40 0.2 H1
lisuride 0.3 5ht1a 20.52 1.08 Alpha1B
Table 4 shows for each drug, the lowest Ki value measured (KiMin) which is the
best-hit, the best-hit receptor (KiMinR), the theoretically lowest measurable npKi
value (npKiLim), the lowest actually measured npKi value (npKiMin), and the
receptor where the lowest npKi value was actually measured (npKiMinR). Drugs
that have both a KiMin value of greater that 100 nm and an npKiMin value
greater than 2.00, have truncated receptor affinity profiles.
doi:10.1371/journal.pone.0009019.t004
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that some distributions are relatively convex (e.g. DMT & LSD),
while others are relatively concave (e.g. DOB & 5-MeO-DMT).
Convexity tends to increase breadth, while concavity tends to
decrease breadth.
It is also useful to present the npKi data of Fig. S2 in numerical
format. In the listing below, the npKi values for each drug are
arranged in decreasing order. A value of 0.00 means that the Ki
value was measured as .10,000 nm. ‘‘ND’’ indicates that the data
is not available. The 5-HT2A and 5-HT2C receptors are also
highlighted in bold font for easier location. npKi values below
about 2.0 should be imperceptible, while values above about 2.0
should be perceptible, and the higher the npKi value, the more
perceptible a receptor should be.
6-F-DMT: 4.00 5ht6, 3.93 5ht2b, 3.80 5ht7, 3.74 H1, 3.66
5ht1d, 3.25 SERT, 3.24 Alpha2C, 3.17 Alpha1A, 3.07 5ht1b, 2.99
Alpha2B, 2.81 5ht1a, 2.74 5ht1e, 2.67 D1, 2.62 D2, 2.58 5ht2c,
2.47 5ht2a, 2.47 D3, 2.45 Imidazoline1, 2.44 H2, 2.43 5ht5a,
2.25 D4, 1.61 D5, 1.57 Sigma1, 1.56 Sigma2; 0.00: DAT, Beta1,
NET, Alpha2A, CB2, CB1, Ca+Channel, Beta2, M2, M3, M4,
M5, M1, Alpha1B, NMDA; ND: DOR, MOR, KOR
DMT: 4.00 5ht7, 3.97 5ht1d, 3.91 5ht2b, 3.53 Alpha2B, 3.53
Alpha2C, 3.51 D1, 3.42 5ht2c, 3.28 5ht1e, 3.25 5ht6, 3.16 5ht5a,
3.13 Imidazoline1, 2.95 Alpha1B, 2.75 Alpha2A, 2.70 Alpha1A,
2.58 5ht2a, 2.37 SERT, 2.23 Sigma1; 0.00: 5ht1a, D4, D5,
Beta1, D2, D3, DAT, NET, 5ht1b, Beta2, Sigma2, CB2, KOR,
Ca+Channel, M1, M2, M3, M4, M5, H2, CB1; ND: H1, DOR,
MOR, NMDA
DPT: 4.00 5ht1a, 3.88 5ht2b, 3.41 H1, 3.31 SERT, 3.05 5ht7,
2.97 Imidazoline1, 2.97 Alpha2B, 2.90 Sigma1, 2.86 Alpha1B,
2.84 Alpha2A, 2.79 Alpha2C, 2.71 5ht1d, 2.57 5ht1b, 2.56
Alpha1A, 2.37 D3, 2.33 DAT, 2.31 5ht2c, 2.20 D4, 2.13 5ht1e,
2.09 5ht2a, 2.04 Sigma2, 1.86 5ht5a, 1.85 5ht6, 1.54 D2; 0.00:
D1, D5, NET, Beta1, DOR, KOR, MOR, Beta2, M2, M3, M4,
M5, M1, H2, CB2, CB1, Ca+Channel, NMDA
DOI: 4.00 5ht2c, 3.79 Alpha2A, 3.52 Beta2, 3.44 5ht2a,
3.13 Alpha2B, 3.13 5ht2b, 3.00 5ht1d, 2.90 M4, 2.89 Beta1, 2.88
Alpha2C, 2.83 SERT, 2.66 5ht1e, 2.51 M3, 2.42 H1, 2.36 M2,
2.34 5ht6, 2.32 M5, 2.31 5ht1a, 2.23 M1, 1.90 5ht7, 1.73 Sigma1,
1.70 Sigma2, 1.67 D1; 0.00: 5ht1b, DAT, Imidazoline1, NET,
5ht5a, DOR, KOR, MOR, Alpha1B, D2, D3, D4, D5, Alpha1A,
H2, CB2, CB1, NMDA; ND: Ca+Channel
LSD: 4.00 5ht1b, 3.77 5ht7, 3.75 5ht6, 3.73 5ht1a, 3.70 5ht1d,
3.64 5ht5a, 3.54 5ht2a, 3.16 D3, 3.11 5ht2b, 3.11 5ht2c, 2.93
Alpha2A, 2.62 5ht1e, 2.55 D2, 2.39 D4, 2.34 D1, 2.05 D5, 1.54
Alpha1A, 1.40 H1, 1.39 Beta1, 1.05 Beta2, 0.65 Alpha1B; 0.00:
KOR, DOR, DAT, SERT, MOR, NET; ND: Sigma2, Alpha2B,
Alpha2C, Imidazoline1, M1, M2, M3, M4, M5, Sigma1, H2,
CB2, CB1, Ca+Channel, NMDA
lisuride: 4.00 5ht1a, 3.88 Alpha2C, 3.78 Alpha2B, 3.22
Alpha2A, 3.01 5ht2b, 2.99 5ht5a, 2.90 D4, 2.74 5ht2a, 2.65 D2,
2.64 5ht7, 2.61 5ht6, 2.56 Beta1, 2.27 5ht1b, 2.09 Alpha1A, 1.93
Beta2, 1.83 5ht1e, 1.59 D5, 1.42 H2, 1.34 D3, 1.08 Alpha1B;
0.00: 5ht1d, 5ht2c, D1, DAT, NET, Imidazoline1, M1, SERT,
CB2, KOR, MOR, M3, M2, M5, M4, CB1, Ca+Channel; ND:
Sigma1, H1, Sigma2, DOR, NMDA
2C-E: 4.00 5ht2b, 3.76 5ht2a, 3.54 5ht1d, 3.44 Alpha2C,
3.38 5ht2c, 3.00 5ht1b, 2.91 Alpha2B, 2.91 5ht1a, 2.77 5ht7,
2.71 Alpha2A, 2.60 5ht1e, 2.27 D3, 2.16 M5, 1.99 M3, 1.93 5ht6,
1.88 D2; 0.00: D1, Alpha1A, Alpha1B, 5ht5a, Beta1, M1, SERT,
D4, NET, Imidazoline1, H1, Sigma2, DOR, KOR, MOR,
NMDA, M2, DAT, M4, D5, CB2, H2, Ca+Channel, CB1; ND:
Sigma1, Beta2
TMA: 4.00 5ht2b, 3.95 Sigma2, 3.95 Sigma1, 3.80 5ht7, 3.45
5ht1a, 3.36 Alpha2A, 3.22 5ht1b, 3.20 5ht1d, 3.15 5ht1e, 3.02
5ht2c, 2.98 Alpha2C; 0.00: 5ht2a, 5ht6, D4, D1, Alpha1A, D2,
D3, Alpha2B, D5, Beta1, Beta2, SERT, DAT, NET, Imidazo-
line1, Alpha1B, 5ht5a, DOR, KOR, MOR, NMDA, M2, CB2,
CB1, M5, H1, H2; ND: M3, M4, Ca+Channel, M1
2C-B: 4.00 5ht2b, 3.71 5ht1d, 3.69 5ht2a, 3.18 5ht2c, 3.12
Alpha2C, 3.11 5ht1b, 3.05 5ht1e, 2.81 5ht7, 2.75 5ht1a, 2.64
Alpha2A, 2.63 5ht6, 2.31 Alpha2B, 2.22 M3, 1.80 Imidazoline1,
1.60 D2, 1.28 D3; 0.00: D1, 5ht5a, Alpha1B, D5, NMDA, M1,
SERT, D4, NET, Alpha1A, Sigma1, Sigma2, DOR, KOR,
MOR, H1, M2, DAT, M4, M5, CB2, H2, CB1; ND: Beta2,
Ca+Channel, Beta1
cis-2a: 4.00 5ht1a, 3.79 5ht1b, 3.46 D3, 3.30 5ht7, 3.25 5ht6,
3.15 5ht5a, 2.89 5ht2a, 2.72 5ht2b, 2.67 D2, 2.49 D4, 2.34
5ht2c, 2.07 5ht1e, 2.00 D1, 1.76 Beta1, 1.66 H1, 1.64 Alpha1A,
1.36 D5, 0.70 Beta2; 0.00: DOR, SERT, MOR, KOR, NET,
DAT, Alpha1B; ND: 5ht1d, Alpha2A, Sigma2, Alpha2B,
Alpha2C, Imidazoline1, M1, M2, M3, M4, M5, Sigma1, H2,
CB2, CB1, Ca+Channel, NMDA
Figure 4. Thirty-five drugs arranged in order of decreasing breadth, increasing selectivity. The thirty-five drugs are arranged in order of
decreasing breadth and increasing selectivity, based on the breadth indices B, Bsq, and Bexp. Although the three indices provide different orderings,
the orderings are quite similar at the two extremes of the table (greatest and least breadth) where most of the attention is likely to be focused. The
drugs with the broadest receptor interactions (least selective) are found at the left of the figure, and the drugs with the narrowest receptor
interactions (most selective) are found at the right of the figure.
doi:10.1371/journal.pone.0009019.g004
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5-MeO-MIPT: 4.00 5ht1a, 3.79 5ht7, 3.74 5ht1d, 3.32 5ht2b,
2.98 5ht6, 2.85 Alpha2A, 2.61 5ht1b, 2.44 5ht2a, 2.29 Alpha2C,
2.15 Imidazoline1, 2.13 Sigma2, 2.11 5ht5a, 1.86 Alpha2B, 1.75
5ht2c, 1.70 D3, 1.55 5ht1e, 1.41 H1, 1.29 D4, 1.28 SERT; 0.00:
D2, Alpha1B, D5, D1, Beta2, NET, DAT, Sigma1, Beta1, DOR,
KOR, MOR, M1, M2, M3, M4, M5, Alpha1A, H2, CB2,
NMDA, Ca+Channel; ND: CB1
Psilocin: 4.00 5ht2b, 3.40 5ht1d, 3.37 D1, 3.03 5ht1e, 2.88
5ht1a, 2.83 5ht5a, 2.82 5ht7, 2.82 5ht6, 2.67 D3, 2.52 5ht2c,
2.19 5ht1b, 2.14 5ht2a, 1.77 Imidazoline1, 1.74 SERT, 1.57
Alpha2B, 1.36 Alpha2A, 1.03 Alpha2C; 0.00: D2, Alpha1B, D5,
D4, Beta2, Beta1, DAT, NET, Alpha1A, Sigma1, Sigma2, DOR,
KOR, MOR, M1, M2, M3, M4, Ca+Channel, H1, H2, CB2,
CB1; ND: M5, NMDA
DIPT: 4.00 5ht1a, 3.53 Imidazoline1, 3.48 5ht2b, 2.98 SERT,
2.83 Sigma1, 2.68 Alpha2C, 2.65 Sigma2, 2.62 Alpha2B, 2.56 D3,
2.55 5ht7, 2.53 H1, 2.51 5ht1d; 0.00: 5ht2a, D4, 5ht5a, D1, D2,
Alpha2A, 5ht6, D5, Beta1, Beta2, 5ht2c, DAT, NET, 5ht1b,
Alpha1B, 5ht1e, DOR, KOR, MOR, M1, M2, M3, M4, M5,
Alpha1A, H2, CB2, CB1, Ca+Channel, NMDA
5-MeO-DIPT: 4.00 5ht1a, 3.91 5ht2b, 3.24 Imidazoline1,
3.03 5ht7, 2.89 5ht1d, 2.72 SERT, 2.66 Alpha2C, 2.64 Sigma2,
2.41 5ht1b, 2.40 Alpha2B, 2.15 Sigma1; 0.00: 5ht5a, 5ht2a, D4,
D3, D1, D2, Alpha2A, 5ht6, D5, Beta1, Beta2, 5ht2c, DAT,
NET, Alpha1A, Alpha1B, 5ht1e, DOR, KOR, MOR, M1, M2,
M3, M4, M5, H1, H2, CB2, CB1, Ca+Channel, NMDA
RR-2b: 4.00 5ht1b, 3.59 5ht1a, 3.20 5ht5a, 3.05 5ht1d, 2.81
5ht7, 2.52 5ht6, 2.40 D3, 2.16 5ht1e, 2.08 D4, 1.88 D2, 1.81
5ht2b, 1.77 D1, 1.63 5ht2c, 1.53 D5, 1.46 5ht2a, 1.14 H1, 0.59
Alpha1A; 0.00: SERT, DOR, KOR, MOR, Alpha1B, NET,
DAT; ND: Alpha2A, Imidazoline1, Beta2, Sigma2, Alpha2B,
Alpha2C, Beta1, M1, M2, M3, M4, M5, Sigma1, H2, CB2, CB1,
Ca+Channel, NMDA
2C-T-2: 4.00 5ht2b, 3.18 5ht2a, 3.05 5ht2c, 2.84 5ht1d,
2.56 Alpha2C, 2.20 5ht1a, 2.16 5ht1e, 1.94 M3, 1.92 Alpha2A,
1.84 5ht1b, 1.79 Alpha2B, 1.79 5ht7, 1.70 Beta2, 1.64 5ht6, 1.60
M5, 1.51 D3, 1.46 Imidazoline1, 1.33 D2, 1.19 Sigma1, 0.81
Beta1; 0.00: D1, 5ht5a, SERT, D4, NET, Alpha1A, Alpha1B,
Sigma2, DOR, KOR, MOR, M1, M2, DAT, M4, D5, H1, H2,
CB2, CB1, Ca+Channel, NMDA
4C-T-2: 4.00 5ht2b, 3.67 Beta2, 3.33 5ht2a, 3.09 5ht2c, 3.05
Sigma1, 2.79 Imidazoline1, 2.66 D3, 2.56 5ht5a, 2.18 5ht7, 2.04
5ht1a, 1.77 5ht1e; 0.00: 5ht6, D1, D4, D5, Alpha1A, Alpha1B,
Alpha2A, Alpha2B, Alpha2C, Beta1, D2, SERT, DAT, NET,
5ht1b, 5ht1d, Sigma2, DOR, KOR, MOR, M1, M2, M3, M4,
M5, H1, H2, CB2, CB1, Ca+Channel, NMDA
MDMA: 4.00 Imidazoline1, 3.64 5ht2b, 3.26 Ca+Channel,
3.21 Alpha2C, 3.09 Alpha2B, 3.07 M3, 2.94 Alpha2A, 2.54 M5,
2.43 M4; 0.00: 5ht2c, 5ht1d, D2, 5ht1e, 5ht1a, 5ht2a, Alpha1A,
Alpha1B, 5ht5a, 5ht6, 5ht7, D1, Beta2, SERT, DAT, NET,
5ht1b, H1, H2, D3, KOR, Beta1, M1, M2, D5, D4, CB1,
NMDA, MOR; ND: DOR, Sigma2, CB2, Sigma1
Ibogaine: 4.00 Sigma2, 3.57 SERT, 3.02 DAT, 3.01 NMDA,
2.88 KOR, 2.67 MOR, 2.55 Sigma1, 2.22 M3, 2.16 5ht2a, 1.96
M1, 1.72 M2, 1.47 D3; 0.00: DOR, 5ht1b, 5ht1d, 5ht1a, H1,
5ht2c, D2, D1, Beta1; ND: Alpha2C, D5, D4, Alpha2B,
Imidazoline1, NET, Alpha2A, 5ht5a, 5ht6, 5ht7, Alpha1B,
5ht1e, 5ht2b, M4, M5, Alpha1A, H2, CB2, CB1, Ca+Channel,
Beta2
DOET: 4.00 5ht1a, 3.72 5ht2a, 3.70 5ht2b, 3.13 5ht2c, 2.40
Alpha2B, 2.07 5ht7, 2.05 Alpha2A, 2.00 Alpha2C, 1.82 Beta2,
1.71 5ht1b, 1.61 5ht1e, 1.40 Beta1, 1.34 5ht1d, 1.18 Sigma2, 1.17
Sigma1; 0.00: D4, Alpha1A, D3, 5ht6, D5, D1, D2, SERT, DAT,
NET, Imidazoline1, Alpha1B, 5ht5a, DOR, KOR, MOR,
NMDA, M2, CB2, CB1, M5, H1, H2; ND: M3, M4,
Ca+Channel, M1
5-MeO-DMT: 4.00 5ht1a, 3.69 5ht7, 3.48 5ht1d, 2.73 5ht6,
2.41 5ht1b, 2.38 D1, 1.84 5ht5a, 1.72 5ht1e, 1.58 D3, 1.57
Alpha2C, 1.55 5ht2c, 1.00 Alpha2A, 0.98 5ht2a, 0.97 SERT,
0.88 Imidazoline1, 0.86 Alpha2B, 0.82 NET, 0.78 D4, 0.73 D2,
0.69 5ht2b; 0.00: Alpha1B, Beta2, Beta1, DAT, D5, Alpha1A,
Sigma1, Sigma2, CB2, KOR, Ca+Channel, M1, M2, M3, M4,
M5, H2, CB1; ND: H1, DOR, MOR, NMDA
SS-2c: 4.00 5ht1a, 3.22 5ht1b, 2.82 D3, 2.45 5ht7, 2.44 5ht6,
2.32 5ht2a, 2.17 5ht5a, 2.17 5ht2b, 2.03 5ht2c, 1.74 D2, 1.72
Beta1, 1.62 D4, 1.16 5ht1e, 1.14 D1, 1.00 D5, 0.67 Alpha1A, 0.57
Beta2, 0.20 H1; 0.00: DOR, SERT, MOR, KOR, NET, DAT,
Alpha1B; ND: 5ht1d, Alpha2A, Sigma2, Alpha2B, Alpha2C,
Imidazoline1, M1, M2, M3, M4, M5, Sigma1, H2, CB2, CB1,
Ca+Channel, NMDA
2C-B-fly: 4.00 5ht2b, 3.81 5ht1d, 2.93 5ht2c, 2.89 5ht2a,
1.91 5ht1e, 1.79 5ht1a, 1.79 Alpha2A, 1.78 5ht6, 1.69 5ht1b, 1.59
Alpha2C, 1.42 M3, 1.24 M4, 1.17 5ht7, 1.16 Alpha2B, 1.15 M1,
1.01 M5, 0.65 M2, 0.26 D1, 0.19 H1, 0.12 D2; 0.00: Beta1,
Alpha1B, 5ht5a, DAT, NET, Imidazoline1, Sigma1, Sigma2,
DOR, KOR, MOR, Beta2, SERT, CB2, D4, D5, Alpha1A, H2,
CB1; ND: D3, Ca+Channel, NMDA
Mescaline: 4.00 Alpha2C, 3.97 5ht2b, 3.61 5ht1a, 3.44
Imidazoline1, 3.16 5ht1e, 2.92 Alpha2A; 0.00: 5ht2a, 5ht2c,
5ht6, 5ht1d, D1, D2, D3, D4, D5, Alpha1A, Alpha1B, 5ht5a,
Alpha2B, 5ht7, Beta1, Beta2, SERT, DAT, NET, 5ht1b, Sigma1,
Sigma2, DOR, KOR, MOR, M1, M2, M3, M4, M5, H1, H2,
CB2, CB1, Ca+Channel, NMDA
DOB: 4.00 5ht2b, 3.23 5ht2a, 2.97 5ht2c, 2.11 Beta2, 1.89
5ht7, 1.82 Alpha2C, 1.79 5ht1d, 1.68 D3, 1.62 5ht1b, 1.53 M3,
1.44 5ht1e, 1.41 Alpha2B, 1.39 Imidazoline1, 1.25 Sigma1, 1.21
Beta1, 1.18 5ht1a, 0.96 Alpha2A, 0.87 5ht5a, 0.85 5ht6, 0.66
SERT, 0.63 H1; 0.00: D5, D2, D4, NET, D1, Alpha1B, Sigma2,
DOR, KOR, MOR, M1, M2, DAT, M4, M5, Alpha1A, H2,
CB2, CB1, Ca+Channel, NMDA
5-MeO-TMT: 4.00 5ht6, 3.62 5ht7, 3.48 5ht1a, 3.38 5ht1d,
2.52 5ht1e, 2.17 5ht2c, 1.97 NET, 1.76 5ht5a; 0.00: 5ht2a,
DAT, D1, D2, D3, D4, D5, H1, H2, SERT, DOR, KOR, MOR;
ND: Beta2, Alpha2A, 5ht2b, 5ht1b, Imidazoline1, Sigma1,
Sigma2, Alpha2B, Alpha2C, Beta1, M1, M2, M3, M4, M5,
Alpha1A, Alpha1B, CB2, CB1, Ca+Channel, NMDA
DOM: 4.00 5ht2b, 3.38 Beta2, 2.75 5ht1d, 2.36 5ht2a, 2.30
Alpha2A, 2.13 Alpha2B, 2.10 Alpha2C, 1.87 5ht7, 1.56 Alpha1A,
1.52 5ht1e, 1.51 5ht1a, 1.47 5ht2c, 1.16 5ht6; 0.00: D3, 5ht1b,
D1, Alpha1B, 5ht5a, D4, D5, Beta1, D2, SERT, DAT, NET,
Imidazoline1, Sigma1, Sigma2, DOR, KOR, MOR, M1, M2,
CB2, CB1, M5, H1, H2, NMDA; ND: M3, Ca+Channel, M4
MDA: 4.00 5ht2b, 3.60 Alpha2C, 3.12 Alpha2B, 2.74
Alpha2A, 2.41 5ht7, 2.38 5ht1a, 2.15 5ht2c; 0.00: 5ht2a,
5ht1e, 5ht1d, D1, D2, D3, D4, 5ht1b, Alpha1A, Alpha1B, 5ht5a,
5ht6, D5, Beta1, Beta2, SERT, DAT, NET, Imidazoline1, CB2,
H2, M5, KOR, M2, CB1; ND: M1, M3, Sigma1, MOR, H1,
Sigma2, DOR, M4, Ca+Channel, NMDA
Aleph-2: 4.00 5ht2b, 2.79 Beta2, 2.50 5ht2c, 2.42 5ht2a,
1.83 Sigma1, 1.70 Imidazoline1, 1.41 D3, 1.08 5ht7, 1.08 SERT,
1.06 Alpha2C, 1.02 5ht1d, 0.98 5ht1a, 0.92 M3, 0.90 5ht1b, 0.74
Alpha2B, 0.72 5ht6, 0.71 5ht1e, 0.44 Alpha2A, 0.37 Beta1, 0.30
M5; 0.00: D1, D2, 5ht5a, D4, NET, Alpha1A, Alpha1B, Sigma2,
DOR, KOR, MOR, M1, M2, DAT, M4, D5, H1, H2, CB2, CB1,
Ca+Channel, NMDA
EMDT: 4.00 5ht6, 2.97 5ht1a, 2.74 5ht1d, 2.73 5ht7, 2.49
5ht1e, 1.95 5ht2c, 1.54 5ht5a; 0.00: 5ht2a, DAT, D5, D1, D2,
D3, D4, NET, H1, H2, SERT, DOR, KOR, MOR; ND: Beta2,
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Alpha2A, 5ht2b, 5ht1b, Imidazoline1, Sigma1, Sigma2, Alpha2B,
Alpha2C, Beta1, M1, M2, M3, M4, M5, Alpha1A, Alpha1B,
CB2, CB1, Ca+Channel, NMDA
TMA-2: 4.00 5ht2b, 3.42 5ht2a, 3.04 H1, 2.58 5ht2c; 0.00:
5ht1b, 5ht1a, 5ht1e, 5ht5a, 5ht6, 5ht7, D1, D2, D3, D4, D5,
5ht1d, Alpha1B, Alpha2A, Alpha2B, Alpha2C, Beta1, Beta2,
SERT, DAT, NET, M5, Alpha1A, H2, M2; ND: KOR, DOR,
M1, MOR, M3, M4, Imidazoline1, Sigma1, Sigma2, CB2, CB1,
Ca+Channel, NMDA
THC: 4.00 CB1, 3.78 CB2; ND: 5ht2a, 5ht2c, 5ht1b, 5ht1d,
5ht1e, 5ht2b, 5ht1a, 5ht7, D1, D2, D3, D4, D5, Alpha1A,
Alpha1B, 5ht5a, 5ht6, Alpha2C, Beta1, Beta2, SERT, DAT,
NET, Imidazoline1, Sigma1, Sigma2, DOR, KOR, MOR, M1,
M2, M3, M4, M5, H1, H2, Alpha2A, Alpha2B, Ca+Channel,
NMDA
MEM: 4.00 5ht2b, 2.21 5ht2a, 2.10 Sigma1, 1.95 5ht7; 0.00:
5ht2c, 5ht1a, 5ht1e, 5ht5a, 5ht6, 5ht1b, D1, D2, D3, D4, D5,
Alpha1A, Alpha1B, Alpha2A, Alpha2B, Alpha2C, Beta1, Beta2,
SERT, DAT, NET, Imidazoline1, 5ht1d, Sigma2, DOR, KOR,
MOR, M1, M2, M3, M4, M5, H1, H2, CB2, CB1, Ca+Channel,
NMDA
Morphine: 4.00 MOR, 2.21 KOR, 0.72 DOR; ND: 5ht2c,
5ht2a, 5ht1d, 5ht1e, 5ht2b, 5ht1a, 5ht1b, D1, D2, D3, D4, D5,
Alpha1A, Alpha1B, Alpha2A, Alpha2B, Alpha2C, Beta1, Beta2,
SERT, DAT, NET, Imidazoline1, Sigma1, Sigma2, 5ht5a, 5ht6,
5ht7, M1, M2, M3, M4, M5, H1, H2, CB2, CB1, Ca+Channel,
NMDA
Salvinorin A: 4.00 KOR; 0.00: 5ht2a, 5ht2b, 5ht2c, 5ht1b,
5ht1d, 5ht1e, 5ht5a, 5ht1a, 5ht7, D1, D2, D3, D4, D5, Alpha1A,
Alpha1B, SERT, DOR, 5ht6, Beta1, Beta2, M2, DAT, M4, M5,
H1, M1, M3, MOR; ND: Alpha2A, Alpha2C, Sigma2, Alpha2B,
NET, Imidazoline1, Sigma1, H2, CB2, CB1, Ca+Channel,
NMDA
Groups of Related Receptors
In addition to looking at breadth at the full complement of forty-
two receptors with which the drugs interact, we can use the Bsq
statistic to look at the participation of selected groups of receptors
(Table S5). 5-HT6 and 5-HT7 are grouped because they share a
common G-protein, Gs [13]. The same data is also presented in
Table S6, which also includes interactions with individual
receptors. Tables S5 and S6 allow us to easily identify drugs with
the greatest or least interaction with an individual receptor or any
group of related receptors.
For example, among drugs with measurable affinity at a 5-HT2
receptor, 5-MeO-DMT has the weakest interaction with both the
three 5-HT2 receptors and the two paradigmatic 5-HT2 receptors
(5-HT2A/C). This can be seen in that 5-MeO-DMT has the lowest
non-zero value in all four of the columns: ‘‘5-HT2,’’ ‘‘5-HT2max,’’
‘‘5-HT2A, 5-HT2C,’’ and ‘‘5-HT2A/Cmax.’’ Meanwhile, the drugs
2C-E and DOI rise to the top of the same four columns, indicating
that they have the strongest interactions with the 5-HT2 receptors
(fourteen drugs tie for the top value in the 5-HT2max column
because thirteen drugs have 5-HT2B as their best hit and one has
5-HT2C as its best hit). LSD has the strongest interaction
collectively with the five dopamine receptors (D1, D2, D3, D4,
D5), the ten assayed 5-HT receptors, and the four assayed 5-HT1
(serotonin-1) receptors. DMT has the strongest interaction with
any single dopamine receptor (Dmax), and is the only drug to have
its best hit at the 5-HT7 receptor (Table S6). Mescaline is the only
drug to have its best hit at an adrenergic receptor (a2C, Table S6).
Ibogaine is the only drug to have its best hit at a sigma receptor.
MDMA is the only drug to have its best hit at an imidazoline
receptor (Table S6). These observations likely provide clues to the
qualitative diversity of these drugs.
Proportional Breadth
There is yet another way to look at the participation of the sub-
sets of receptors. It may be relevant to consider the participation of
a sub-set of receptors in proportion to the participation of all
receptors (Table S7). For this we use the proportional breadth
statistic (Bp) described in the methods section. The same data is
also displayed in Table S8.
The proportional breadth statistic, Bp, is strongly influenced by
the degree of overall breadth of the drug (Bsq
2), as this determines
the denominator in calculating the proportion. Therefore, we find
MEM at the top of the 5-HT column because it is almost
completely selective for a single receptor, 5-HT2B. Similarly,
TMA-2 is at the top of the 5-HT2 columns because it is highly
selective for the 5-HT2 receptors, and EMDT is at the top of the
‘‘5-HT6, 5-HT7’’ column because it is highly selective for the 5-
HT6 receptor. Due to their high degree of selectivity, MEM,
TMA-2, and EMDT all have small denominators in calculating
the Bp statistic.
More interesting cases involve less selective drugs. For example,
DMT is a very promiscuous drug, yet it falls at the top of the ‘‘a1A,
a1B’’ column. MDA falls at the top of the ‘‘Adrenergic’’ and ‘‘a2A,
a2B, a2C’’ columns. 5-MeO-DMT appears third from the top of
the ‘‘5-HT6, 5-HT7’’ column and second from the top of the ‘‘5-
HT7’’ column (Table S8). Ibogaine appears at the top of the ‘‘s1,
s2’’ column. Although fairly selective, TMA-2’s position at the top
of the ‘‘H1, H2’’ column represents an important aspect of its
pharmacology, likewise for DOM’s position at the top of the ‘‘b1,
b2’’ column.
Profiles of Receptors
The B statistics can also be used to look at the relative role
played by the various receptors in the pharmacology of the entire
set of drugs of this study. In this case, for each receptor, we sum
the npKi values at each receptor across each of the thirty-five
drugs. In Table 5 we can see the rankings from the three B
statistics. The data in Table 5 can also be represented graphically
(Fig. 5). The three B statistics provide a very consistent ranking for
the top seven receptors. In descending order of importance: 5-
HT2B, 5-HT1A, 5-HT7, 5-HT1D, 5-HT2A, 5-HT2C, a2C (with
some play between the sixth and seventh positions). This set of top
receptors would be a good place to look for receptors other than 5-
HT2A and 5-HT2C, which play an important role in the actions of
psychedelic drugs.
Fig. S3 is a more detailed graphical view of data presented in
Table 5. The receptors are presented in order of decreasing
breadth (Bsq). The figures for each individual receptor provide
information on the relative importance of each receptor at each
drug, similar to that in Table S5 and Table S6. Receptors at the
top of the figure have the broadest interactions with the thirty-five
drugs, while receptors at the bottom of the figure have the
narrowest interactions with the thirty-five drugs. The black vertical
bars represent a 100-fold drop in affinity relative to the receptor
with the highest affinity at each drug. As a rule of thumb, this is
presumed to be the limit of perceptible receptor interaction. Drugs
to the right of the black bar should have imperceptible interactions
with the receptor, while drugs to the left of the black bar should
have perceptible interactions with the receptor, increasingly so the
further left they are. It is also useful to present the npKi data of Fig.
S3 in numerical format. npKi values below about 2.0 should be
imperceptible, while values above about 2.0 should be perceptible,
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and the higher the npKi value, the more perceptible a receptor
should be at a particular drug.
5ht2b: 4.00 DOB, 4.00 MDA, 4.00 Aleph-2, 4.00 2C-B-fly,
4.00 2C-B, 4.00 TMA, 4.00 psilocin, 4.00 TMA-2, 4.00 2C-E,
4.00 2C-T-2, 4.00 4C-T-2, 4.00 MEM, 4.00 DOM, 3.97
mescaline, 3.93 6-F-DMT, 3.91 5-MeO-DIPT, 3.91 DMT, 3.88
DPT, 3.70 DOET, 3.64 MDMA, 3.48 DIPT, 3.32 5-MeO-MIPT,
3.13 DOI, 3.11 LSD, 3.01 lisuride, 2.72 cis-2a, 2.17 SS-2c, 1.81
RR-2b, 0.69 5-MeO-DMT; 0.00 salvinorin A; ND: 5-MeO-
TMT, ibogaine, EMDT, morphine, THC
5ht1a: 4.00 5-MeO-MIPT, 4.00 lisuride, 4.00 DOET, 4.00 SS-
2c, 4.00 5-MeO-DIPT, 4.00 DIPT, 4.00 5-MeO-DMT, 4.00 cis-
2a, 4.00 DPT, 3.73 LSD, 3.61 mescaline, 3.59 RR-2b, 3.48 5-
MeO-TMT, 3.45 TMA, 2.97 EMDT, 2.91 2C-E, 2.88 psilocin,
2.81 6-F-DMT, 2.75 2C-B, 2.38 MDA, 2.31 DOI, 2.20 2C-T-2,
2.04 4C-T-2, 1.79 2C-B-fly, 1.51 DOM, 1.18 DOB, 0.98 Aleph-2;
0.00: TMA-2, MEM, MDMA, DMT, ibogaine, salvinorin A;
ND: morphine, THC
5ht7: 4.00 DMT, 3.80 6-F-DMT, 3.80 TMA, 3.79 5-MeO-
MIPT, 3.77 LSD, 3.69 5-MeO-DMT, 3.62 5-MeO-TMT, 3.30
cis-2a, 3.05 DPT, 3.03 5-MeO-DIPT, 2.82 psilocin, 2.81 2C-B,
2.81 RR-2b, 2.77 2C-E, 2.73 EMDT, 2.64 lisuride, 2.55 DIPT,
2.45 SS-2c, 2.41 MDA, 2.18 4C-T-2, 2.07 DOET, 1.95 MEM,
1.90 DOI, 1.89 DOB, 1.87 DOM, 1.79 2C-T-2, 1.17 2C-B-fly,
1.08 Aleph-2; 0.00: TMA-2, MDMA, mescaline, salvinorin A;
ND: ibogaine, morphine, THC
5ht1d: 3.97 DMT, 3.81 2C-B-fly, 3.74 5-MeO-MIPT, 3.71
2C-B, 3.70 LSD, 3.66 6-F-DMT, 3.54 2C-E, 3.48 5-MeO-DMT,
3.40 psilocin, 3.38 5-MeO-TMT, 3.20 TMA, 3.05 RR-2b, 3.00
DOI, 2.89 5-MeO-DIPT, 2.84 2C-T-2, 2.75 DOM, 2.74 EMDT,
2.71 DPT, 2.51 DIPT, 1.79 DOB, 1.34 DOET, 1.02 Aleph-2;
0.00: 4C-T-2, mescaline, TMA-2, MEM, lisuride, MDMA,
salvinorin A, MDA, ibogaine; ND: cis-2a, SS-2c, morphine,
THC
5ht2a: 3.76 2C-E, 3.72 DOET, 3.69 2C-B, 3.54 LSD, 3.44
DOI, 3.42 TMA-2, 3.33 4C-T-2, 3.23 DOB, 3.18 2C-T-2, 2.89
2C-B-fly, 2.89 cis-2a, 2.74 lisuride, 2.58 DMT, 2.47 6-F-DMT,
2.44 5-MeO-MIPT, 2.42 Aleph-2, 2.36 DOM, 2.32 SS-2c, 2.21
MEM, 2.16 ibogaine, 2.14 psilocin, 2.09 DPT, 1.46 RR-2b, 0.98
5-MeO-DMT; 0.00: TMA, DIPT, MDA, MDMA, mescaline, 5-
MeO-TMT, EMDT, 5-MeO-DIPT, salvinorin A; ND: morphine,
THC
5ht2c: 4.00 DOI, 3.42 DMT, 3.38 2C-E, 3.18 2C-B, 3.13
DOET, 3.11 LSD, 3.09 4C-T-2, 3.05 2C-T-2, 3.02 TMA, 2.97
DOB, 2.93 2C-B-fly, 2.58 TMA-2, 2.58 6-F-DMT, 2.52 psilocin,
2.50 Aleph-2, 2.34 cis-2a, 2.31 DPT, 2.17 5-MeO-TMT, 2.15
MDA, 2.03 SS-2c, 1.95 EMDT, 1.75 5-MeO-MIPT, 1.63 RR-2b,
1.55 5-MeO-DMT, 1.47 DOM; 0.00: 5-MeO-DIPT, mescaline,
lisuride, MEM, MDMA, DIPT, ibogaine, salvinorin A; ND:
morphine, THC
Alpha2C: 4.00 mescaline, 3.88 lisuride, 3.60 MDA, 3.53
DMT, 3.44 2C-E, 3.24 6-F-DMT, 3.21 MDMA, 3.12 2C-B, 2.98
TMA, 2.88 DOI, 2.79 DPT, 2.68 DIPT, 2.66 5-MeO-DIPT, 2.56
2C-T-2, 2.29 5-MeO-MIPT, 2.10 DOM, 2.00 DOET, 1.82 DOB,
1.59 2C-B-fly, 1.57 5-MeO-DMT, 1.06 Aleph-2, 1.03 psilocin;
0.00: 4C-T-2, MEM, TMA-2; ND: LSD, cis-2a, RR-2b, SS-2c,
5-MeO-TMT, EMDT, ibogaine, salvinorin A, morphine, THC
5ht6: 4.00 6-F-DMT, 4.00 EMDT, 4.00 5-MeO-TMT, 3.75
LSD, 3.25 cis-2a, 3.25 DMT, 2.98 5-MeO-MIPT, 2.82 psilocin,
2.73 5-MeO-DMT, 2.63 2C-B, 2.61 lisuride, 2.52 RR-2b, 2.44
SS-2c, 2.34 DOI, 1.93 2C-E, 1.85 DPT, 1.78 2C-B-fly, 1.64 2C-
T-2, 1.16 DOM, 0.85 DOB, 0.72 Aleph-2; 0.00: 4C-T-2, 5-
MeO-DIPT, mescaline, TMA, TMA-2, MDA, DOET, MEM,
MDMA, DIPT, salvinorin A; ND: ibogaine, morphine, THC
Table 5. Forty-two receptors arranged in order of decreasing
interaction with the full set of thirty-five drugs.
B Receptor Bsq Receptor Bexp Receptor
102.400 5ht2b 19.479 5ht2b 7.094 5ht2b
82.564 5ht1a 16.634 5ht1a 6.709 5ht1a
75.736 5ht7 14.931 5ht7 6.348 5ht7
66.217 5ht1d 14.574 5ht1d 6.348 5ht1d
65.462 5ht2a 13.806 5ht2a 6.153 5ht2a
64.798 5ht2c 13.352 5ht2c 6.071 Alpha2C
58.020 Alpha2C 12.989 Alpha2C 6.037 5ht2c
55.055 5ht1e 12.430 5ht6 6.034 5ht6
53.236 5ht6 11.951 5ht1b 5.930 5ht1b
49.634 5ht1b 11.508 5ht1e 5.722 Alpha2A
47.526 Alpha2A 11.304 Alpha2A 5.709 Alpha2B
46.760 Alpha2B 11.138 Alpha2B 5.666 5ht1e
38.823 D3 10.097 Imidazoline1 5.608 Imidazoline1
36.702 Imidazoline1 9.741 5ht5a 5.450 5ht5a
36.079 5ht5a 9.561 D3 5.348 D3
30.487 Sigma1 8.657 Sigma1 5.271 Sigma1
26.764 SERT 8.448 SERT 5.252 SERT
23.237 Beta2 7.831 Beta2 5.248 Sigma2
21.839 Sigma2 7.808 Sigma2 5.170 Beta2
21.769 H1 7.452 H1 5.080 H1
21.302 D2 7.296 D1 4.985 D1
21.107 D1 6.697 D2 4.732 D2
17.995 D4 6.278 D4 4.732 KOR
17.821 M3 6.205 M3 4.649 D4
16.510 Alpha1A 6.043 Alpha1A 4.644 Alpha1A
14.117 Beta1 5.401 KOR 4.643 M3
9.935 M5 5.209 Beta1 4.626 MOR
9.137 D5 4.812 MOR 4.484 CB1
9.089 KOR 4.492 M5 4.425 Beta1
7.540 Alpha1B 4.297 Alpha1B 4.355 CB2
6.674 MOR 4.000 CB1 4.282 Alpha1B
6.563 M4 3.978 M4 4.243 M5
5.344 DAT 3.810 DAT 4.173 M4
5.334 M1 3.809 D5 4.154 DAT
4.727 M2 3.782 CB2 4.097 Ca+Channel
4.000 CB1 3.263 Ca+Channel 4.059 D5
3.861 H2 3.181 M1 3.995 NMDA
3.783 CB2 3.013 NMDA 3.942 M1
3.263 Ca+Channel 2.992 M2 3.914 M2
3.013 NMDA 2.824 H2 3.884 H2
2.796 NET 2.138 NET 3.749 NET
0.720 DOR 0.720 DOR 3.585 DOR
The forty-two receptors are arranged in order of decreasing interaction with the
full set of thirty-five drugs, based on the breadth statistics B, Bsq. and Bexp. The
receptors with the greatest interactions are found at the tops of the columns,
and the receptors with the least interactions are found at the bottoms of the
columns.
doi:10.1371/journal.pone.0009019.t005
Psychedelics Human Receptorome
PLoS ONE | www.plosone.org 11 February 2010 | Volume 5 | Issue 2 | e9019
5ht1b: 4.00 LSD, 4.00 RR-2b, 3.79 cis-2a, 3.22 SS-2c, 3.22
TMA, 3.11 2C-B, 3.07 6-F-DMT, 3.00 2C-E, 2.61 5-MeO-MIPT,
2.57 DPT, 2.41 5-MeO-DIPT, 2.41 5-MeO-DMT, 2.27 lisuride,
2.19 psilocin, 1.84 2C-T-2, 1.71 DOET, 1.69 2C-B-fly, 1.62
DOB, 0.90 Aleph-2; 0.00: 4C-T-2, MDMA, mescaline, DMT,
DIPT, TMA-2, DOM, MDA, DOI, MEM, ibogaine, salvinorin
A; ND: 5-MeO-TMT, EMDT, morphine, THC
5ht1e: 3.28 DMT, 3.16 mescaline, 3.15 TMA, 3.05 2C-B, 3.03
psilocin, 2.74 6-F-DMT, 2.66 DOI, 2.62 LSD, 2.60 2C-E, 2.52 5-
MeO-TMT, 2.49 EMDT, 2.16 2C-T-2, 2.16 RR-2b, 2.13 DPT,
2.07 cis-2a, 1.91 2C-B-fly, 1.83 lisuride, 1.77 4C-T-2, 1.72 5-MeO-
DMT, 1.61 DOET, 1.55 5-MeO-MIPT, 1.52 DOM, 1.44 DOB,
1.16 SS-2c, 0.71 Aleph-2; 0.00: 5-MeO-DIPT, TMA-2, MDA,
MEM,MDMA, DIPT, salvinorin A;ND: ibogaine, morphine, THC
Alpha2A: 3.79 DOI, 3.36 TMA, 3.22 lisuride, 2.94 MDMA,
2.93 LSD, 2.92 mescaline, 2.85 5-MeO-MIPT, 2.84 DPT, 2.75
DMT, 2.74 MDA, 2.71 2C-E, 2.64 2C-B, 2.30 DOM, 2.05
DOET, 1.92 2C-T-2, 1.79 2C-B-fly, 1.36 psilocin, 1.00 5-MeO-
DMT, 0.96 DOB, 0.44 Aleph-2; 0.00: 4C-T-2, DIPT, 5-MeO-
DIPT, MEM, TMA-2, 6-F-DMT; ND: cis-2a, RR-2b, SS-2c, 5-
MeO-TMT, EMDT, ibogaine, salvinorin A, morphine, THC
Alpha2B: 3.78 lisuride, 3.53 DMT, 3.13 DOI, 3.12 MDA,
3.09 MDMA, 2.99 6-F-DMT, 2.97 DPT, 2.91 2C-E, 2.62 DIPT,
2.40 DOET, 2.40 5-MeO-DIPT, 2.31 2C-B, 2.13 DOM, 1.86 5-
MeO-MIPT, 1.79 2C-T-2, 1.57 psilocin, 1.41 DOB, 1.16 2C-B-
fly, 0.86 5-MeO-DMT, 0.74 Aleph-2; 0.00: 4C-T-2, mescaline,
TMA, MEM, TMA-2; ND: LSD, cis-2a, RR-2b, SS-2c, 5-MeO-
TMT, EMDT, ibogaine, salvinorin A, morphine, THC
Imidazoline1: 4.00 MDMA, 3.53 DIPT, 3.44 mescaline, 3.24
5-MeO-DIPT, 3.13 DMT, 2.97 DPT, 2.79 4C-T-2, 2.45 6-F-
DMT, 2.15 5-MeO-MIPT, 1.80 2C-B, 1.77 psilocin, 1.70 Aleph-
2, 1.46 2C-T-2, 1.39 DOB, 0.88 5-MeO-DMT; 0.00:MEM, 2C-
E, MDA, lisuride, DOI, 2C-B-fly, DOM, TMA, DOET; ND:
TMA-2, LSD, cis-2a, RR-2b, SS-2c, 5-MeO-TMT, EMDT,
ibogaine, salvinorin A, morphine, THC
5ht5a: 3.64 LSD, 3.20 RR-2b, 3.16 DMT, 3.15 cis-2a, 2.99
lisuride, 2.83 psilocin, 2.56 4C-T-2, 2.43 6-F-DMT, 2.17 SS-2c,
2.11 5-MeO-MIPT, 1.86 DPT, 1.84 5-MeO-DMT, 1.76 5-MeO-
TMT, 1.54 EMDT, 0.87 DOB; 0.00: MDMA, 5-MeO-DIPT,
2C-B, MDA, mescaline, 2C-B-fly, DOI, TMA, DOET, TMA-2,
2C-E, 2C-T-2, Aleph-2, MEM, DOM, DIPT, salvinorin A; ND:
ibogaine, morphine, THC
D3: 3.46 cis-2a, 3.16 LSD, 2.82 SS-2c, 2.67 psilocin, 2.66 4C-
T-2, 2.56 DIPT, 2.47 6-F-DMT, 2.40 RR-2b, 2.37 DPT, 2.27 2C-
E, 1.70 5-MeO-MIPT, 1.68 DOB, 1.58 5-MeO-DMT, 1.51 2C-
T-2, 1.47 ibogaine, 1.41 Aleph-2, 1.34 lisuride, 1.28 2C-B; 0.00:
MDMA, mescaline, MEM, DMT, TMA, DOET, TMA-2, DOM,
MDA, DOI, salvinorin A, 5-MeO-TMT, EMDT, 5-MeO-DIPT;
ND: 2C-B-fly, morphine, THC
Sigma1: 3.95 TMA, 3.05 4C-T-2, 2.90 DPT, 2.83 DIPT, 2.55
ibogaine, 2.23 DMT, 2.15 5-MeO-DIPT, 2.10 MEM, 1.83 Aleph-
2, 1.73 DOI, 1.57 6-F-DMT, 1.25 DOB, 1.19 2C-T-2, 1.17
DOET; 0.00: 2C-B, mescaline, 5-MeO-MIPT, DOM, 2C-B-fly,
5-MeO-DMT, psilocin; ND: 2C-E, lisuride, MDA, TMA-2, LSD,
cis-2a, MDMA, SS-2c, 5-MeO-TMT, EMDT, RR-2b, salvinorin
A, morphine, THC
SERT: 3.57 ibogaine, 3.31 DPT, 3.25 6-F-DMT, 2.98 DIPT,
2.83 DOI, 2.72 5-MeO-DIPT, 2.37 DMT, 1.74 psilocin, 1.28 5-
MeO-MIPT, 1.08 Aleph-2, 0.97 5-MeO-DMT, 0.66 DOB; 0.00:
2C-E, MDA, 2C-B, mescaline, 4C-T-2, 2C-T-2, lisuride, MEM,
2C-B-fly, DOM, TMA, MDMA, TMA-2, LSD, cis-2a, RR-2b,
SS-2c, 5-MeO-TMT, EMDT, DOET, salvinorin A; ND:
morphine, THC
Beta2: 3.67 4C-T-2, 3.52 DOI, 3.38 DOM, 2.79 Aleph-2, 2.11
DOB, 1.93 lisuride, 1.82 DOET, 1.70 2C-T-2, 1.05 LSD, 0.70 cis-
2a, 0.57 SS-2c; 0.00: 5-MeO-DMT, DMT, mescaline, DIPT,
DPT, 5-MeO-MIPT, 6-F-DMT, 5-MeO-DIPT, MDMA, 2C-B-
fly, psilocin, TMA, TMA-2, MDA, MEM, salvinorin A; ND: 2C-
B, 2C-E, RR-2b, 5-MeO-TMT, ibogaine, EMDT, morphine,
THC
Figure 5. Forty-two receptors arranged in order of decreasing interaction with the full set of thirty-five drugs. The forty-two receptors
are arranged in order of decreasing interaction with the full set of thirty-five drugs, based on the breadth statistics, B, Bsq. and Bexp. The receptors with
the greatest interactions are found at the left of the figures, and the receptors with the least interactions are found at the right of the figures. The
black vertical bars represent a 100-fold drop in affinity relative to the receptor with the highest affinity at each drug. As a rule of thumb, this is
presumed to be the limit of perceptible receptor interaction. Drugs to the right of the black bar should have imperceptible interactions with the
receptor, while drugs to the left of the black bar should have perceptible interactions with the receptor, increasingly so the further left they are.
doi:10.1371/journal.pone.0009019.g005
Psychedelics Human Receptorome
PLoS ONE | www.plosone.org 12 February 2010 | Volume 5 | Issue 2 | e9019
Sigma2: 4.00 ibogaine, 3.95 TMA, 2.65 DIPT, 2.64 5-MeO-
DIPT, 2.13 5-MeO-MIPT, 2.04 DPT, 1.70 DOI, 1.56 6-F-DMT,
1.18 DOET; 0.00: 2C-T-2, 2C-E, mescaline, 2C-B, DOB, Aleph-
2, MEM, 4C-T-2, DOM, DMT, 5-MeO-DMT, 2C-B-fly,
psilocin; ND: lisuride, MDA, TMA-2, LSD, cis-2a, MDMA, SS-
2c, 5-MeO-TMT, EMDT, RR-2b, salvinorin A, morphine, THC
H1: 3.74 6-F-DMT, 3.41 DPT, 3.04 TMA-2, 2.53 DIPT, 2.42
DOI, 1.66 cis-2a, 1.41 5-MeO-MIPT, 1.40 LSD, 1.14 RR-2b,
0.63 DOB, 0.20 SS-2c, 0.19 2C-B-fly; 0.00: psilocin, 2C-B, 5-
MeO-DIPT, TMA, 4C-T-2, 2C-E, 2C-T-2, MDMA, mescaline,
DOM, EMDT, DOET, salvinorin A, 5-MeO-TMT, MEM,
Aleph-2, ibogaine; ND: lisuride, DMT, MDA, 5-MeO-DMT,
morphine, THC
D1: 3.51 DMT, 3.37 psilocin, 2.67 6-F-DMT, 2.38 5-MeO-
DMT, 2.34 LSD, 2.00 cis-2a, 1.77 RR-2b, 1.67 DOI, 1.14 SS-2c,
0.26 2C-B-fly; 0.00: 2C-B, MDA, 5-MeO-MIPT, DIPT, 5-MeO-
DIPT, DPT, 4C-T-2, DOB, lisuride, MDMA, mescaline, DOM,
TMA, DOET, TMA-2, 2C-E, 2C-T-2, Aleph-2, MEM, 5-MeO-
TMT, EMDT, ibogaine, salvinorin A; ND: morphine, THC
D2: 2.67 cis-2a, 2.65 lisuride, 2.62 6-F-DMT, 2.55 LSD, 1.88
RR-2b, 1.88 2C-E, 1.74 SS-2c, 1.60 2C-B, 1.54 DPT, 1.33 2C-T-
2, 0.73 5-MeO-DMT, 0.12 2C-B-fly; 0.00: psilocin, 5-MeO-
MIPT, 5-MeO-DIPT, DMT, 4C-T-2, DIPT, MDMA, DOI,
mescaline, DOM, TMA, DOET, TMA-2, DOB, MDA, Aleph-2,
MEM, 5-MeO-TMT, EMDT, ibogaine, salvinorin A; ND:
morphine, THC
D4: 2.90 lisuride, 2.49 cis-2a, 2.39 LSD, 2.25 6-F-DMT, 2.20
DPT, 2.08 RR-2b, 1.62 SS-2c, 1.29 5-MeO-MIPT, 0.78 5-MeO-
DMT; 0.00: psilocin, MDMA, DMT, 2C-B, DIPT, 5-MeO-
DIPT, mescaline, 4C-T-2, DOB, MDA, DOI, 2C-B-fly, DOM,
TMA, DOET, TMA-2, 2C-E, 2C-T-2, Aleph-2, MEM, 5-MeO-
TMT, EMDT, salvinorin A; ND: ibogaine, morphine, THC
M3: 3.07 MDMA, 2.51 DOI, 2.22 2C-B, 2.22 ibogaine, 1.99
2C-E, 1.94 2C-T-2, 1.53 DOB, 1.42 2C-B-fly, 0.92 Aleph-2;
0.00: DMT, lisuride, 5-MeO-DMT, 5-MeO-MIPT, DIPT,
psilocin, DPT, 4C-T-2, 6-F-DMT, mescaline, MEM, salvinorin
A, 5-MeO-DIPT; ND: MDA, DOM, TMA, LSD, cis-2a, RR-2b,
SS-2c, 5-MeO-TMT, EMDT, DOET, TMA-2, morphine,
THC
Alpha1A: 3.17 6-F-DMT, 2.70 DMT, 2.56 DPT, 2.09 lisuride,
1.64 cis-2a, 1.56 DOM, 1.54 LSD, 0.67 SS-2c, 0.59 RR-2b; 0.00:
psilocin, MDMA, mescaline, 5-MeO-MIPT, DIPT, 5-MeO-
DIPT, 5-MeO-DMT, 4C-T-2, DOB, MDA, DOI, 2C-B-fly, 2C-
B, TMA, DOET, TMA-2, 2C-E, 2C-T-2, Aleph-2, MEM,
salvinorin A; ND: 5-MeO-TMT, ibogaine, EMDT, morphine,
THC
KOR: 4.00 salvinorin A, 2.88 ibogaine, 2.21 morphine; 0.00:
MDA, 2C-B, DMT, MDMA, mescaline, DOB, 2C-T-2, Aleph-2,
MEM, 5-MeO-MIPT, DIPT, psilocin, 5-MeO-DMT, 2C-E, LSD,
lisuride, DOI, 2C-B-fly, DOM, TMA, DOET, DPT, 4C-T-2, cis-
2a, RR-2b, SS-2c, 5-MeO-TMT, EMDT, 5-MeO-DIPT; ND:
TMA-2, 6-F-DMT, THC
Beta1: 2.89 DOI, 2.56 lisuride, 1.76 cis-2a, 1.72 SS-2c, 1.40
DOET, 1.39 LSD, 1.21 DOB, 0.81 2C-T-2, 0.37 Aleph-2; 0.00:
5-MeO-DMT, DMT, mescaline, DOM, DIPT, 5-MeO-MIPT,
DPT, 4C-T-2, 6-F-DMT, 5-MeO-DIPT, MDMA, 2C-B-fly, 2C-
E, TMA, psilocin, TMA-2, ibogaine, MDA, MEM, salvinorin A;
ND: 2C-B, 5-MeO-TMT, RR-2b, EMDT, morphine, THC
MOR: 4.00 morphine, 2.67 ibogaine; 0.00: lisuride, mescaline,
2C-B, TMA, MDMA, DPT, DOB, 2C-T-2, Aleph-2, MEM, 5-
MeO-MIPT, DIPT, psilocin, DOET, 2C-E, LSD, cis-2a, DOI,
2C-B-fly, DOM, EMDT, 5-MeO-DIPT, salvinorin A, 4C-T-2,
SS-2c, RR-2b, 5-MeO-TMT; ND: MDA, DMT, 5-MeO-DMT,
TMA-2, 6-F-DMT, THC
M5: 2.54 MDMA, 2.32 DOI, 2.16 2C-E, 1.60 2C-T-2, 1.01
2C-B-fly, 0.30 Aleph-2; 0.00: 2C-B, DMT, DOB, MDA, DOET,
5-MeO-DMT, 5-MeO-MIPT, DIPT, 5-MeO-DIPT, DPT, 4C-T-
2, 6-F-DMT, lisuride, MEM, mescaline, DOM, TMA, TMA-2,
salvinorin A; ND: psilocin, LSD, RR-2b, cis-2a, 5-MeO-TMT,
EMDT, ibogaine, SS-2c, morphine, THC
Alpha1B: 2.95 DMT, 2.86 DPT, 1.08 lisuride, 0.65 LSD;
0.00:MDMA, 2C-B, psilocin, mescaline, DOB, 2C-T-2, Aleph-2,
MEM, 5-MeO-MIPT, DIPT, 5-MeO-DIPT, 5-MeO-DMT, 4C-
T-2, 6-F-DMT, MDA, DOI, 2C-B-fly, DOM, TMA, DOET,
TMA-2, 2C-E, cis-2a, RR-2b, SS-2c, salvinorin A; ND: 5-MeO-
TMT, ibogaine, EMDT, morphine, THC
CB1: 4.00 THC; 0.00: MDA, MDMA, mescaline, 2C-B,
DMT, psilocin, 5-MeO-DMT, 2C-E, 2C-T-2, Aleph-2, MEM,
2C-B-fly, DIPT, 5-MeO-DIPT, DPT, 4C-T-2, DOB, lisuride,
DOI, TMA, DOM, 6-F-DMT, DOET; ND: 5-MeO-MIPT,
LSD, TMA-2, RR-2b, SS-2c, 5-MeO-TMT, EMDT, ibogaine,
salvinorin A, morphine, cis-2a
M4: 2.90 DOI, 2.43 MDMA, 1.24 2C-B-fly; 0.00: DOB, 2C-
B, lisuride, psilocin, DMT, 2C-E, 2C-T-2, Aleph-2, 5-MeO-
DMT, 5-MeO-MIPT, DIPT, 5-MeO-DIPT, DPT, 4C-T-2, 6-F-
DMT, mescaline, MEM, salvinorin A; ND: DOM, MDA,
DOET, TMA, LSD, cis-2a, RR-2b, SS-2c, 5-MeO-TMT,
EMDT, ibogaine, TMA-2, morphine, THC
DAT: 3.02 ibogaine, 2.33 DPT; 0.00: DOB, MDA, 2C-B,
DMT, MDMA, mescaline, 2C-E, 2C-T-2, Aleph-2, MEM, 5-
MeO-MIPT, DIPT, psilocin, 5-MeO-DMT, 4C-T-2, 6-F-DMT,
lisuride, DOI, 2C-B-fly, DOM, TMA, DOET, TMA-2, LSD, cis-
2a, RR-2b, SS-2c, 5-MeO-TMT, EMDT, 5-MeO-DIPT, salvi-
norin A; ND: morphine, THC
D5: 2.05 LSD, 1.61 6-F-DMT, 1.59 lisuride, 1.53 RR-2b, 1.36
cis-2a, 1.00 SS-2c; 0.00: psilocin, 5-MeO-DMT, 2C-B, DMT,
MDMA, mescaline, 5-MeO-MIPT, DIPT, 5-MeO-DIPT, DPT,
4C-T-2, DOB, MDA, DOI, 2C-B-fly, DOM, TMA, DOET,
TMA-2, 2C-E, 2C-T-2, Aleph-2, MEM, 5-MeO-TMT, EMDT,
salvinorin A; ND: ibogaine, morphine, THC
CB2: 3.78 THC; 0.00: MDA, DOI, mescaline, 2C-B, DMT,
psilocin, 5-MeO-DMT, 2C-E, 2C-T-2, Aleph-2, MEM, 5-MeO-
MIPT, DIPT, 5-MeO-DIPT, DPT, 4C-T-2, DOB, lisuride,
DOET, 2C-B-fly, DOM, TMA, 6-F-DMT; ND: MDMA, LSD,
TMA-2, RR-2b, SS-2c, 5-MeO-TMT, EMDT, ibogaine, salvi-
norin A, morphine, cis-2a
Ca+Channel: 3.26 MDMA; 0.00: lisuride, DOB, mescaline,
5-MeO-MIPT, DMT, psilocin, 5-MeO-DMT, 2C-E, 2C-T-2,
Aleph-2, MEM, 4C-T-2, DIPT, 5-MeO-DIPT, DPT, 6-F-DMT;
ND: 2C-B, MDA, DOI, 2C-B-fly, DOM, TMA, DOET, TMA-2,
LSD, cis-2a, RR-2b, SS-2c, 5-MeO-TMT, EMDT, ibogaine,
salvinorin A, morphine, THC
M1: 2.23 DOI, 1.96 ibogaine, 1.15 2C-B-fly; 0.00: lisuride,
DOB, DMT, 2C-B, 5-MeO-DMT, 2C-E, 2C-T-2, Aleph-2,
MEM, 5-MeO-MIPT, DIPT, psilocin, DPT, 4C-T-2, 6-F-DMT,
mescaline, MDMA, salvinorin A, DOM, 5-MeO-DIPT; ND:
MDA, TMA, LSD, cis-2a, RR-2b, SS-2c, 5-MeO-TMT, EMDT,
DOET, TMA-2, morphine, THC
NMDA: 3.01 ibogaine; 0.00: 2C-T-2, DOB, mescaline, 2C-B,
TMA, MDMA, DPT, 2C-E, 6-F-DMT, Aleph-2, MEM, 5-MeO-
MIPT, DIPT, DOET, 5-MeO-DIPT, 4C-T-2, DOM, DOI; ND:
lisuride, 2C-B-fly, MDA, DMT, 5-MeO-DMT, TMA-2, LSD, cis-
2a, RR-2b, SS-2c, 5-MeO-TMT, EMDT, psilocin, salvinorin A,
morphine, THC
M2: 2.36 DOI, 1.72 ibogaine, 0.65 2C-B-fly; 0.00: MDA,
DOB, DMT, 2C-B, 5-MeO-DMT, 2C-E, 2C-T-2, Aleph-2,
MEM, 5-MeO-MIPT, DIPT, psilocin, DPT, 4C-T-2, 6-F-DMT,
lisuride, MDMA, mescaline, DOM, TMA, DOET, TMA-2, 5-
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MeO-DIPT, salvinorin A; ND: LSD, cis-2a, 5-MeO-TMT,
EMDT, RR-2b, SS-2c, morphine, THC
H2: 2.44 6-F-DMT, 1.42 lisuride; 0.00: MDMA, mescaline,
2C-B, DMT, psilocin, 5-MeO-DMT, 2C-E, 2C-T-2, Aleph-2,
MEM, 5-MeO-MIPT, DIPT, 5-MeO-DIPT, DPT, 4C-T-2,
DOB, MDA, DOI, 2C-B-fly, DOM, TMA, DOET, TMA-2, 5-
MeO-TMT, EMDT; ND: RR-2b, SS-2c, LSD, cis-2a, ibogaine,
salvinorin A, morphine, THC
NET: 1.97 5-MeO-TMT, 0.82 5-MeO-DMT; 0.00: MDMA,
MDA, DOB, DMT, psilocin, mescaline, 2C-E, 2C-T-2, Aleph-2,
MEM, 2C-B, DIPT, 5-MeO-DIPT, DPT, 4C-T-2, 6-F-DMT,
lisuride, DOI, 2C-B-fly, DOM, TMA, DOET, TMA-2, LSD, cis-
2a, RR-2b, SS-2c, 5-MeO-MIPT, EMDT; ND: ibogaine,
salvinorin A, morphine, THC
DOR: 0.72 morphine; 0.00: 2C-T-2, DOI, mescaline, 2C-B,
TMA, psilocin, DPT, DOB, LSD, Aleph-2, MEM, 5-MeO-MIPT,
DIPT, 5-MeO-DIPT, DOET, 2C-E, 4C-T-2, cis-2a, RR-2b, 2C-
B-fly, DOM, EMDT, ibogaine, salvinorin A, 5-MeO-TMT, SS-
2c; ND: MDMA, lisuride, MDA, DMT, 5-MeO-DMT, TMA-2,
6-F-DMT, THC
Activity Data
The NIMH-PDSP provided activity data for the twenty-five
drugs of Fig. 1, for 5-HT2A and 5-HT2C (Table S3). While most
compounds appear to be full agonists at the two receptors, there
are a few exceptions. Lower values of activity were reported for
psilocin, MDMA, DOM and the three control drugs: 4C-T-2, 6-
fluoro-DMT, and lisuride.
Discussion
Perhaps the most striking result of the NIMH-PDSP assays has
been to show that the psychedelics interact with a large number of
receptors (forty-two of the forty-nine sites at which most of the
drugs were assayed). While the phenylalkylamines tend to be more
selective than the tryptamines and ergolines, they generally can
not be accurately characterized as selective for 5-HT2, as they are
so widely described in the literature [1,4,6,7,14,15]. Only DOB
and MEM come close to fitting that description. Ironically, DOI
has been one of the drugs of choice in studies of the molecular
pharmacology of psychedelics, and has been widely assumed to be
a 5-HT2-selective agent [4,6,7,15,16]. This study has revealed
DOI to be one of the least selective of all psychedelics. Some of the
literature on DOI may need to be reinterpreted. The same may be
true of any studies whose conclusions rely on the assumption that
psychedelics are selective. Studies requiring drugs selective for 5-
HT2 should be conducted with DOB or MEM, and they should
not be presented as typical or characteristic of psychedelics.
In addition to showing that psychedelics are not as selective as
generally believed, the data presented also shows that they exhibit
diverse patterns of receptor interactions. Different drugs empha-
size different classes of receptors. 5-HT2B is the best hit for thirteen
drugs, and 5-HT1A is the best hit for nine drugs. Five of the top six
psychedelic receptors (Table 5) are 5-HT1 and 5-HT2 receptors. If
we acknowledge the pervasiveness of the 5-HT1 and 5-HT2
receptors, and then look past them, we find that the set of thirty-
five drugs emphasize a wide variety of receptors:
5-HT1A DOET
5-HT1D 2C-B-fly
5-HT2 DOB, 2C-T-2
5-HT2B MEM
5-HT5A RR-2b
5-HT6 EMDT, 5-MeO-TMT, 6-F-DMT
5-HT7 DMT, 5-MeO-MIPT, LSD, 5-MeO-DMT
a2A DOI
a2C mescaline, lisuride, MDA, 2C-E
b2 DOM, 2C-B, Aleph-2, 4C-T-2
H1 TMA-2, DPT
s2 ibogaine, TMA
D1 psilocin
D3 cis-2a, SS-2c
I1 MDMA, DIPT, 5-MeO-DIPT
k salvinorin A
m morphine
CB1 THC
It should be possible to use this diverse set of drugs as probes
into the roles played by the various receptor systems in the human
mind. In the papers that follow, this possibility will be explored by
synthesizing the NIMH-PDSP data together with the data on the
human pharmacology of these drugs.
Supporting Information
Figure S1 Receptor affinity profiles of psychedelic drugs,
ordered by receptor type. The vertical axis is normalized pKi
(npKi). Horizontal axis is a list of forty-two receptors, grouped by
receptor type. The drugs are ordered to correspond roughly to
similarity of structure and receptor affinity profiles. Colors
correspond to classes of receptors. It can be seen at a glance that
most, but not all of the drugs interact strongly with the serotonin
receptors (beige), certain drugs interact strongly with the dopamine
receptors (red), others with the adrenergic receptors (green), yet
others with the histamine receptors (yellow), etc.
Found at: doi:10.1371/journal.pone.0009019.s001 (0.14 MB
DOC)
Figure S2 Receptor affinity profiles of psychedelic drugs,
ordered by decreasing affinity. The vertical axis is normalized
pKi (npKi). Horizontal axis is a list of forty-two receptors,
arranged in order of decreasing affinity for each individual drug.
The thirty-five drugs are arranged in order of decreasing breadth,
based on the Bsq values of Table 3 and Fig. 4. Drugs at the top of
the figure have the broadest receptor interactions (least selective),
while drugs at the bottom of the figure have the narrowest receptor
interactions (most selective). Colors correspond to classes of
receptors, and are the same as used in Fig. S1. The black vertical
bars represent a 100-fold drop in affinity relative to the receptor
with the highest affinity. As a rule of thumb, this is presumed to be
the limit of perceptible receptor interaction. Receptors to the right
of the black bar should be imperceptible, while receptors to the left
of the black bar should be perceptible, increasingly so the further
left they are.
Found at: doi:10.1371/journal.pone.0009019.s002 (0.18 MB
DOC)
Figure S3 Receptor affinities at forty-two receptors across thirty-
five drugs, ordered by decreasing breadth of receptor. The vertical
axis is normalized pKi (npKi). Horizontal axis is a list of thirty-five
drugs, ordered by decreasing affinity at the receptor. The forty-two
receptors are arranged in order of decreasing breadth, based on
the Bsq values of Table 5 and Fig. 5. Receptors at the top of the
figure have the broadest interactions with the thirty-five drugs,
while receptors at the bottom of the figure have the narrowest
interactions with the thirty-five drugs. The black vertical bars
represent a 100-fold drop in affinity relative to the receptor with
the highest affinity at each drug. As a rule of thumb, this is
presumed to be the limit of perceptible receptor interaction. Drugs
to the right of the black bar should have imperceptible interactions
with the receptor, while drugs to the left of the black bar should
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have perceptible interactions with the receptor, increasingly so the
further left they are.
Found at: doi:10.1371/journal.pone.0009019.s003 (0.20 MB
DOC)
Table S1 Receptor affinity data for ibogaine. Table S1 reports
receptor affinity data for ibogaine collected from the literature.
The columns identify the receptor, the species from which the
receptor was used, the tissue from which the receptor was used, the
radioligand used in determining affinity, the Ki value in
nanomoles or the IC50 value in nanomoles, and the literature
reference from which the data was obtained.
Found at: doi:10.1371/journal.pone.0009019.s004 (0.31 MB
DOC)
Table S2 Raw affinity (Ki) data for thirty-five drugs at sixty-seven
sites. The table has been divided into three sections. The first section
displays forty-two sites at which most compounds were assayed and
at least one ‘‘hit’’ (Ki,10,000 nm) was found (5ht1a, 5ht1b, 5ht1d,
5ht1e, 5ht2a, 5ht2b, 5ht2c, 5ht5a, 5ht6, 5ht7, D1, D2, D3, D4, D5,
Alpha1A, Alpha1B, Alpha2A, Alpha2B, Alpha2C, Beta1, Beta2,
SERT, DAT, NET, Imidazoline1, Sigma1, Sigma2, DOR, KOR,
MOR, M1, M2, M3, M4, M5, H1, H2, CB1, CB2, Ca+Channel,
NMDA/MK801). The second section displays seven sites at which
most compounds were assayed, but at which there were no hits
(5ht3, H3, H4, V1, V2, V3, GabaA). The third section displays the
remaining eighteen sites, at which only a few compounds were
assayed, and no hits were found (GabaB, mGluR1a, mGluR2,
mGluR4, mGluR5, mGluR6, mGluR8, A2B2, A2B4, A3B2, A3B4,
A4B2, A4B2**, A4B4, BZP (a1), EP3, MDR 1, PCP). Missing Ki
values are indicated by ‘‘ND’’ meaning that no data is available, or
by ‘‘PH’’ meaning that the primary assay ‘‘hit’’ (.50% inhibition),
but the secondary assay was not performed. For the first section of
the table, an extra row and column labeled ‘‘ND/PH’’ provides a
count of missing Ki data in the two categories, for each compound
and for each receptor.
Found at: doi:10.1371/journal.pone.0009019.s005 (0.05 MB
XLS)
Table S3 Activity data for twenty-five drugs at 5-HT2A and 5-
HT2C. GF62 is the cell line that expresses the 5-HT2A receptor,
and INI is the cell line that expresses the 5-HT2C receptor. The
‘‘EC50 nM’’ columns express the concentration that gives half of
the maximal activity for that drug. The maximal activity is
displayed in the ‘‘Emax6SEM’’ column, and represent Ca++
mobilization relative to 5-HT which should give an Emax value of
100%. Data for the drugs should produce lower Emax values. For
a compound that gives, for example, 53% Emax, the EC50 is the
concentration where 26.5% response occurs. Emax values above
100%6SEM are an artifact caused by extrapolation by the
graphpad program when it doesn’t have points at the top end to
define the asymptote. The data represent the mean 6 variance of
computer-derived estimates from single experiments done in
quadruplicate. Thus, the four observations are averaged and a
single estimate with error is provided.
Found at: doi:10.1371/journal.pone.0009019.s006 (0.13 MB
DOC)
Table S4 Affinity (Ki) data transformed into pKi values for
thirty-five drugs at forty-two sites. Table S4 presents the raw Ki
data transformed into pKi values. Higher affinities produce lower
Ki values, thus it is valuable to calculate: pKi =2log10(Ki).
Higher affinities have higher pKi values, and each unit of pKi
value corresponds to one order of magnitude of Ki value. ND
means the data is not available, and UM means that Ki was
measured as .10,000 nm. Generally, the highest Ki value
generated by NIMH-PDSP is 10,000, which produces a pKi
value of 24 (although a value of 10,450 was reported for 5-MeO-
TMT). For non-PDSP data gathered from the literature, some
values greater than 10,000 are reported (i.e. 12,500, 14,142,
22,486, 39,409 and 70,000 for ibogaine).
Found at: doi:10.1371/journal.pone.0009019.s007 (0.04 MB
XLS)
Table S5 Thirty-five drugs arranged in order of decreasing
breadth at selected groups of receptors. The thirty-five drugs are
arranged in order of decreasing breadth at groups of receptors,
based on the breadth index Bsq. The drugs with the broadest
receptor interactions within the group are found at the tops of the
columns, and the drugs with the least receptor interactions are
found at the bottoms of the columns. Some columns list the
maximum npKi value for a group of receptors (e.g. 5-HT2max).
In this example, the column lists the highest npKi value of the
three 5-HT2 receptors (5-HT2A, 5-HT2B, and 5-HT2C). An
entry of ‘‘ND’’ indicates that the statistic could not be calculated
because some data is missing. For example, to calculate Bsq for 5-
HT2, or npKi for 5-HT2max, we need npKi values for 5-HT2A,
5-HT2B, and 5-HT2C. If any one of the three values is missing,
the statistics will be reported as ND. Values of 0.00 correspond to
Ki values of.10,000. The same data is also presented in Table S6
Receptors in a group are listed in the column heading, or are
represented with the following abbreviations: N 5-HT - 5-HT1A,
5-HT1B, 5-HT1D, 5-HT1E, 5-HT2A, 5-HT2B, 5-HT2C, 5-
HT5A, 5-HT6, 5-HT7 N 5-HT2 - 5-HT2A, 5-HT2B, 5-HT2C
N 5-HT2max - maximum of 5-HT2A, 5-HT2B, 5-HT2C N 5-
HT2A/Cmax - maximum of 5-HT2A, 5-HT2C N 5-HT1 - 5-
HT1A, 5-HT1B, 5-HT1D, 5-HT1E N 5-HT1max - maximum of
5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E N Dmax - maximum of D1,
D2, D3, D4, D5 N Adrenergic - a1A, a1B, a2A, a2B, a2C, b1, b2
N AdrenergicMax - maximum of a1A, a1B, a2A, a2B, a2C, b1,
b2 N a1max - maximum of a1A, a1B N a2max - maximum of
a2A, a2B, a2C N bmax - maximum of b1, b2 N Hmax -
maximum of H1, H2 N smax - maximum of s1, s 2 N Mmax -
maximum of M1, M2, M3, M4, M5 N TransportersMax -
maximum of SERT, DAT, NET N OpioidMax - maximum of
DOR, KOR, MOR
Found at: doi:10.1371/journal.pone.0009019.s008 (0.61 MB
DOC)
Table S6 Table of npKi, Bsq, or npKimax values at individual
or groups of receptors for thirty-five drugs. Table S6 presents the
normalized pKi data (npKi) for thirty five drugs at forty-two
receptors, transporters and ion channels. In addition, it presents
the three breadth statistics (B, Bsq, Bexp) for each drug across all
forty-two sites, the breadth statistic Bsq for sixteen groups of
related sites, and the maximum npKi value for thirteen groups of
related sites. A useful way to work with the table is to choose a
column, and sort the data on that column (click ‘‘Data, ‘‘Sort,’’
select ‘‘Header row,’’ choose the column from the ‘‘Sort by’’ drop
down and select ‘‘Descending,’’ finally clicking ‘‘OK’’). Missing
values are reported as ‘‘ND.’’ Values of 0.0000 correspond to Ki
values of .10,000. Receptors in a group are listed in the column
headings using the following abbreviations: N B - sum of npKi
values across forty-two receptors N Bsq - square root of sum of
squares of npKi values across forty-two receptors N Bexp - log of
sum of exponents of npKi values across forty-two receptors N 5ht -
5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT2A, 5-HT2B, 5-
HT2C, 5-HT5A, 5-HT6, 5-HT7 N 5ht1 - 5-HT1A, 5-HT1B, 5-
HT1D, 5-HT1E N 5ht1max - maximum of 5-HT1A, 5-HT1B, 5-
HT1D, 5-HT1E N 5ht2 - 5-HT2A, 5-HT2B, 5-HT2C
N 5ht2max - maximum of 5-HT2A, 5-HT2B, 5-HT2C
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N 5ht2[ac] - 5-HT2A, 5-HT2C N 5ht2[ac]max - maximum of 5-
HT2A, 5-HT2C N 5ht[67] - 5-HT6, 5-HT7 N D[1–5] - D1, D2,
D3, D4, D5 N D[1–5]max - maximum of D1, D2, D3, D4, D5
N ‘[AB] - a1A, a1B, a2A, a2B, a2C, b1, b2 N ‘[AB]max -
maximum of a1A, a1B, a2A, a2B, a2C, b1, b2 N Alpha1 - a1A,
a1B N Alpha1max - maximum of a1A, a1B N Alpha2 - a2A,
a2B, a2C N Alpha2max - maximum of a2A, a2B, a2C N Beta -
b1, b2 N BetaMax - maximum of b1, b2 N M[1–5] - M1, M2,
M3, M4, M5 N M[1–5]max - maximum of M1, M2, M3, M4, M5
N Sigma - s1,s 2 N SigmaMax - maximum ofs1,s 2 N H[12] -
H1, H2 N H[1–2]max - maximum of H1, H2 N T$ - SERT,
DAT, NET N T$max - maximum of SERT, DAT, NET
N [DKM]OR - DOR, KOR, MOR N [DKM]ORmax -
maximum of DOR, KOR, MOR N CB[12] - CB1, CB2
Found at: doi:10.1371/journal.pone.0009019.s009 (0.05 MB
XLS)
Table S7 Thirty-five drugs arranged in order of decreasing
proportional interaction at selected groups of receptors. The
thirty-five drugs are arranged in order of decreasing proportional
interaction at groups of receptors, based on the proportional
breadth index Bp. The drugs with the greatest proportional
interactions are found at the tops of the columns, and the drugs
with the least proportional interactions are found at the bottoms of
the columns. An entry of ‘‘ND’’ indicates that the statistic could
not be calculated because some data is missing. The same data is
also presented in Table S8. Receptors in a group are listed in the
column heading, or are represented with the following abbrevi-
ations: N 5-HT - 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-
HT2A, 5-HT2B, 5-HT2C, 5-HT5A, 5-HT6, 5-HT7 N 5-HT1 -
5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E N Adrenergic - a1A, a1B,
a2A, a2B, a2C, b1, b2
Found at: doi:10.1371/journal.pone.0009019.s010 (0.37 MB
DOC)
Table S8 Table of Bp values at individual or groups of receptors
for thirty-five drugs. Table S8 presents the proportional breadth
statistic Bp for each drug at each of forty-two sites, and for sixteen
groups of related sites. A useful way to work with the table is to
choose a column, and sort the data on that column (click ‘‘Data,
‘‘Sort,’’ select ‘‘Header row,’’ choose the column from the ‘‘Sort
by’’ drop down and select ‘‘Descending,’’ finally clicking ‘‘OK’’).
Missing values are reported as ‘‘ND.’’ Receptors in a group are
listed in the column headings using the following abbreviations:
N Bsq - square root of sum of squares of npKi values across forty-
two receptors N 5ht - 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-
HT2A, 5-HT2B, 5-HT2C, 5-HT5A, 5-HT6, 5-HT7 N 5ht1 - 5-
HT1A, 5-HT1B, 5-HT1D, 5-HT1E N 5ht2 - 5-HT2A, 5-HT2B,
5-HT2C N 5ht2[ac] - 5-HT2A, 5-HT2C N 5ht[67] - 5-HT6, 5-
HT7 N D[1–5] - D1, D2, D3, D4, D5 N ‘[AB] - a1A, a1B, a2A,
a2B, a2C, b1, b2 N Alpha1 - a1A, a1B N Alpha2 - a2A, a2B,
a2C N Beta - b1, b2 N M[1–5] - M1, M2, M3, M4, M5
N Sigma - s1, s 2 N H[12] - H1, H2 N T$ - SERT, DAT,
NET N [DKM]OR - DOR, KOR, MOR N CB[12] - CB1, CB2
Found at: doi:10.1371/journal.pone.0009019.s011 (0.04 MB
XLS)
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